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THE DECISION MAKING PROCESS IN WOMEN DIAGNOSED WITH ESTROGEN 
RECEPTOR-POSITIVE BREAST CANCER EXPERIENCING SIDE EFFECTS 
RELATED TO ORAL ENDOCRINE THERAPY 
Oral endocrine therapy (OET) is standard therapy for millions of estrogen 
receptor-positive breast cancer survivors (ER+BCS). OET reduces recurrence, mortality, 
and metastasis. ER+BCS often do not take their OET as recommended due to adverse 
side effects. The purpose of this dissertation was to develop an explanatory framework 
of decision making by women with ER+ breast cancer who report experiencing side 
effects from OET. This project was comprised of two components.  
The first component was a systematic review with three main findings: (1) side 
effects negatively impact OET non-adherence, (2) there is an absence of decisional 
supports provided to or available for ER+BCS who are experiencing OET side effects,, 
and (3) ER+BCS likely have unmet decisional needs related to OET.  
The second component was a grounded theory study that included 31 ER+BCS 
reporting OET side effects. During a single semi-structured interview, participants 
described the experience of OET over time. This study produced two qualitatively 
derived projects. 
 First, a theoretical framework was developed that depicted four stages through 
which the experience of OET decision making unfolded. The stages were (1) being told 
what I need to do to live, (2) doing what I need to do to live, (3) enduring what I need to 
do to live, and (4) deciding how I want to live.  
Second, a typology was developed that depicted six sources of external 
decisional supports (healthcare providers, husbands, other breast cancer survivors, 
friends and family, the internet and other media sources, and God) that met four types of 
vi 
decisional needs (information about OET and its side effects, in-depth discussions about 
side effects, help in managing side effects, and emotional support). 
 Findings can be used to develop interventions, such as decision aids, to 
promote quality decision making in women experiencing OET side effects. 
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Chapter 1 
1.1 Introduction 
This chapter provides an overview of the dissertation topic on oral endocrine 
therapy (OET) decision making by women with estrogen receptor positive (ER+)  breast 
cancer who report experiencing side effects. The chapter includes a discussion on the 
significance of the topic, the study purpose and specific aims, and the study approach. 
The results of this dissertation are disseminated in three papers, which are presented in 
chapters 2, 3, and 4, respectively.  
1.2 Significance 
The importance of OET 
Breast cancer is the most common cancer among women in the United States.1 
About 232,670 new cases of breast cancer were diagnosed in the United States in 
2014.1 Currently, there are more than 2.8 million breast cancer survivors (BCS) living in 
the United States. About 75% of all breast cancer diagnoses are ER+,1 and these 
women receive a recommendation for OET,1 which is prescribed to prevent 
reoccurrence by blocking certain hormones that fuel cancer growth. Examples of OET 
are selective estrogen receptor modulators (e.g., Tamoxifen) given to pre-menopausal 
women, and aromatase inhibitors (e.g., letrozole) given to post-menopausal women. 
These medications block estrogen from binding at receptor sites or stop the peripheral 
conversion of androgens to estrogen. Tamoxifen has been shown to decrease 
recurrence by 41% and mortality by 34%, whereas aromatase inhibitors have been 
shown to reduce recurrence by 30-41%, metastasis by 16-18%,2,3 and mortality at rates 
similar to tamoxifen.17,23  
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Adherence to OET 
Adherence is defined as the extent to which a person’s health behaviors 
correspond with agreed-upon recommendations from a healthcare provider.24 Many 
women with breast cancer do not take their OET as recommended. Using the PubMed 
search engine, a systematic review was conducted to determine rates of adherence to 
OET in breast cancer survivors.25 The review included 19 relevant articles and data from 
26,631 women. The findings revealed that 64-88% of women decided to initiate OET 
and among these 30-50% of women were non-adherent to daily or twice daily pill 
ingestion, and 70% were non-adherent by discontinuing OET prior to the recommended 
5 year period.7,10,26-42 These rates include women who have tried one or more OETs.  
OET adherence as a decision making process unfolding over time 
OET adherence is not a single event decision, but rather is a psychosocial 
process unfolding over time. Health related decision making in women is a psychosocial 
process, and throughout the duration of the recommended 5 year period the decision to 
initiate, adhere, or prematurely stop OET occurs within a social context. Using the 
framework of Walker and Avant,43 a concept analysis was conducted to understand 
health-related decision making in women. Following a careful review of 19 relevant 
articles, attributes defining health-related decision making were determined. These 
indicated that (1) decision making occurs between two people or groups of people, (2) 
women must be aware that a decision needs to be made, (3) women must be able to 
clearly understand the health information being presented to them, (4) unrestricted 
communication of risks and benefits must occur, and (5) a woman’s preferences must be 
taken into consideration.44-61 The identified attributes demonstrate the psychosocial 
process of health related decision making in women. In addition, social interactions with 
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providers, family, friends, and mainstream media have been shown to specifically 
influence OET decision making in women who have experienced OET side 
effects.15,16,18,20,21,62 Therefore, decision making regarding OET is best considered a 
psychosocial process where the social interaction between a women and her 
environment influences the psychological process of deciding.  
Side effects and OET decision making 
Although our understanding of OET decision making is limited non-adherence is 
a common response to OET side effects.5-8,10,11,20,27,63-69 Side effects caused by 
Tamoxifen include hot flushes, sleep problems, weight gain and loss of libido, and less 
commonly thromboembolic disease or endometrial pathologies.20 Aromatase inhibitors 
also cause hot flushes and have been associated with arthralgia, sleep problems, 
increased fractures, rash, and gastrointestinal upset.20 A systematic review aimed at 
reporting the current state of the science of OET adherence and side effects was 
conducted. Using the PubMed search engine, 24 relevant articles representing 11,044 
women showed that women who report OET side effects are 2 to 4 times more likely to 
discontinue therapy earlier than 5 years,5,6,8,9,14 and women who report severe side 
effects are 5 times more likely to discontinue therapy earlier than 5 years.9 Qualitative 
research also reports women purposely interrupting OET to temporarily avoid side 
effects. This is evident from narrations such as “I never saw the doctor I just took it upon 
myself to stop the medication and I thought I’m going to start them again, so I started 
them again and although I felt little bits of nausea it wasn’t nearly as bad… so I’ve just 
kept on taking them since”.19 Some women attempt to eliminate side effects through 
switching their OET.11,20,69 Unfortunately, although side effects cause women to switch 
OETs, switching did not prevent further side effects or decisions to interrupt or stop 
OET.11 In one study of 503 women,83 (17%) decided to switch to a different aromatase 
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inhibitor due to side effects and among those, only 32 (38.6%) continued the therapy for 
a median of 13.7 months.11 
The Ottawa Decision Support Framework (ODSF) 
Knowing how women make decisions about OET, particularly when experiencing 
side effects, is foundational to quality OET decision making. Quality decisions are 
defined as decisions that are informed and based on an individual’s values.12 The ODSF 
suggests that quality decisions are based on a patient’s understanding of decisional 
needs and availability of decisional supports.12 Decisional needs are defined as a 
person’s need that results in a difficulty to make a decision.12 Decisional needs are 
based on the knowledge, degree of certainty, expectations, and values one may have 
regarding the decision to be made.12,13 Decisional support is defined as any support that 
is given to meet an identified decisional need.12 The goal of decisional support is to 
address modifiable determinants of decision making that are suboptimal. These 
determinants can include inadequate knowledge, unrealistic expectations, unclear 
values, unclear norms, unwanted pressure, inadequate support, and inadequate 
personal and external resources to make the decision.12,13,62  Optimal decision making 
involves low levels of decisional conflict (uncertainty about course of action to take when 
choice involves risk, or challenge to personal life values) and decisional regret 
(disappointment with decision) and results in high levels of decisional satisfaction (high 
quality decision where chosen option matches patient preference).12  
Missing decisional support 
When the decision making process is well-understood, decisional support often 
comes in the form of a decision aid. A decision aid is an intervention that helps patients 
make specific and deliberative choices among the available options. Decision aids often 
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provide information on treatment options and outcomes relevant to a person’s health 
status, and include methods to clarify values.47 The Patient Decision Aids Research 
Group affiliated with the Ottawa Hospital Research Institute is an international research 
team that designs and tests decision aids and decisional support training programs for 
patients and health practitioners. The group manages a database of decision aids that 
can be uploaded and shared if they adhere to established guidelines that include the 
following: (1) meets the definition of a decision aid, (2) is not more than 5 years old, (3) 
provides references to scientific evidence, and (4) is publicly available.12 There is only 
one relevant decisional support tool that exists in this database. It is a decision aid for 
OET that focuses only on post-menopausal women making the initial decision to initiate 
therapy and does not take into consideration OET side effects or decision making as a 
process unfolding over time.22 
Unmet decisional needs 
Women are inadequately informed about OET side effects and are therefore 
likely to have unmet decisional needs. Information has been consistently shown to 
influence behavior in women, both generally,21 and in those with a diagnosis of breast 
cancer.70,71  Several studies have indicated that women receive insufficient information 
regarding OET and OET side effects.11,14-18 A systematic review was conducted with an 
aim to understand how information on OET side effects influenced OET adherence. 
Eleven relevant articles were identified in the PubMed database.8,9,14-16,18-21,62,72,73 
Findings showed that women seek additional information related to their OET side 
effects because the information they had been provided was not sufficient.8,14-16,19-21 
Sources of information provided to the women were from provider,8,14-16,19,21 peer,15 and 
media (internet, television, and books).8,15,19,20 The review demonstrated that women 
receive insufficient information regarding OET and OET side effects, and that women 
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report being in distress because information from providers lacks specificity about the 
cause of OET side effects.15  
In another qualitative study, women reported seeking additional information from 
media sources (internet, television, and books), because the side effect information they 
had received from their physicians was inadequate.19 However, research has shown that 
the accuracy of available information can vary depending on its source.74-76 Women who 
report experiencing OET side effects and have inadequate decisional support may be 
seeking information from inaccurate sources in order to meet their decisional needs. 
Summary 
Information is needed about how women who receive OET make decisions about 
their therapy, especially when they report experiencing side effects. By obtaining first-
person narratives of women who have been prescribed OET, the goals of the 
dissertation were to develop an explanatory framework that describes their OET 
experience as it unfolds over time and their salient decisional needs and decisional 
supports. A grounded theory approach was used to allow the basic psychosocial 
process of decision making to emerge naturally.  
1.3 Study Purpose and Specific Aims 
The purpose of this study was to develop an explanatory framework of decision 
making by women with ER+ breast cancer who reported experiencing side effects. This 
study had four specific aims: 
Aim 1: Describe responses to OET side effects among women with ER+ breast cancer. 
Aim 2: Identify common decisional needs of women with ER+ breast cancer who report 
experiencing OET side effects. 
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Aim 3: Identify common decisional supports sought by and provided to women with ER+ 
breast cancer who report experiencing OET side effects. 
Aim 4: Describe how women with ER+ breast cancer who report experiencing OET side 
effects experience OET over time. 
The framework developed from this study will provide foundational information for 
understanding women’s experience with OET as it unfolds over time. This information 
will ultimately be useful for developing decisional support materials aimed at meeting 
decisional needs and improving OET decisional quality. As a result of this program of 
research, there may be better congruence between a woman’s decisional needs and the 
decisional support she receives. 
1.4 Approach  
Design 
A grounded theory approach was used to develop the explanatory 
framework.77,78 Grounded theory describes the responses of people sharing a common 
challenge. This methodology focuses on the complexities of people undergoing change, 
the influence of social interactions and social context on the phenomenon of interest, 
and critical junctures in psychosocial processes.79 For this study, grounded theory was 
the most appropriate method due to the following reasons: (1) women with ER+ breast 
cancer share the common challenge of OET and its side effects; (2) decision making 
related to OET is best understood as a complex process that changes over time and is 
driven by women’s decisional needs; and (3) the process is influenced by sociocultural 
context, including decisional supports. Women who reported experiencing OET side 
effects participated in a single face-to-face interview (see Figure 1.1).  
8 
Figure 1.1: Study Design 
 
Sample 
Inclusion criteria and their rationale were the following: (1) women (breast cancer 
rarely occurs in men); (2) aged between 40 and 75 (breast cancer rarely occurs in 
children, and age limit will control for the developmental stage of childbearing and for 
possible cognitive changes that occurs with aging; (3) first-time diagnosis of ER+ non-
metastatic breast cancer (to ensure no previous recommendation for OET); (4) 
completed primary therapy (finished with chemotherapy, radiation, and surgery – may be 
taking Herceptin); (5) received a prescription for OET and initiated therapy 6-24 months 
ago (literature shows that this timeframe allows for the experience of side effects and a 
response to the side effects. E.g., switching or discontinuation of OET)11; (6) reported 
having had side effects from OET (target population); and (7) fluent in English (a 
translator is outside the scope of this study). Exclusion criteria were: (1) had a health 
proxy or guardian making decisions on their behalf; (2) self-reported current or previous 
diagnosis of serious mental disorder (e.g., schizophrenia, psychosis, or dementia); or (3) 
self-reported inability to recall OET decision making over time (to assure robust recall of 
the phenomenon). 
Additional rationale: In grounded theory, participants are initially selected 
because they have knowledge of the phenomenon being studied (in this study it was 
OET). Because the narratives of women who decide to discontinue OET are needed to 
fully understand the decision making process over time, women were included 
regardless of whether they were taking OET at the time of the study interview. In 
Recruitment Screening Consent and 
Interview (N=31) 
9 
addition, the timing for inclusion allowed for a narrative description of the OET 
experience as it unfolded over time.  
Sample size  
A purposive sample (n=31) was recruited. An exact determination of sample size 
could not be established a priori and was dictated by the emerging explanatory 
framework. Grounded theory methodologists recommend a sample size with 20 to 50 
participants, but the final number is related to the heterogeneity of the sample and the 
complexity of the research questions.80,81 Because the participants shared the same 
challenge (the experience of OET and its side effects) and the theoretical framework 
focused on the primary phenomena of decision making, it was anticipated that 
approximately 30 women would be adequate to achieve the study purpose and the 
specific aims. The final sample included 31 participants. Based on prior adherence 
studies,2-4 it was estimated that approximately 19 to 26 participants (63 to 87%) would 
be taking OET at the time of the interview, and 4 to 11 (13 to 37%) would have 
discontinued OET. At the time of the interview, 12 participants (38.7%) were on their 
original tamoxifen, 1 participant (3.2%) was on tamoxifen after switching from AI, 8 
participants (25.0%) were on their original Aromatase inhibitors (AI) prescription, 2 
participants (6.5%) were on AI after switching from Tamoxifen, 3 participants (9.6%) 
were on a different AI after switching from their original AI, 4 participants (12.9%) 
stopped after original OET and did not switch to another,  and 1 participant (3.2%) 
stopped after switching OET. 
Study procedures  
Institutional review and approval: The study protocol was approved by the IUSCC 
Scientific Review Committee and the Indiana University Institutional Review Board. A 
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waiver of written informed consent and written authorization was requested and 
approved by Institutional Review Board.   
Recruitment 
Several recruitment strategies were used. First, the primary researcher placed 
study fliers announcing the study in local hospitals and clinic locations where women 
diagnosed with breast cancer were likely to frequent, such as clinic waiting rooms and 
hospital parking garages. Second, the primary researcher created a Facebook study 
page. Facebook page sharing with breast cancer groups and Facebook paid advertising 
were used to notify potentially eligible women of the study. Third, local agencies that 
supported minority breast cancer survivors emailed study notifications to local women. 
Fourth, with the assistance of local physician collaborators, study invitations were 
directly mailed to the homes of potentially eligible women identified through clinic- and 
registry-based databases.  Women interested in learning more about the study were 
invited to telephone or email the study team. 
Eligibility screening and scheduling the study visit 
Women were contacted and screened for eligibility over the phone. The study 
was explained using a study information sheet. If eligible, name and contact information 
were retained and the study visit was scheduled. The majority of women were 
interviewed over the phone.  
Data collection and measures 
During the interview appointment, prior to the start of any data collection, a study 
information sheet was reviewed with the women. It included language about 
authorization to use protected health information. Data collection included: 
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• A demographic and treatment information form (see appendix). Self-reported 
treatment information was provided by the participant. All data on this form were used to 
describe the sample.  
• A minimally structured interview (60 min) with open-ended questions about the 
participant’s OET decision making process was conducted using the interview guide 
(see appendix). Although the interview guide set the parameters of the interview, the 
questions were open-ended and administered with flexibility in order to provide an 
opportunity for participants to describe salient experiences from their own perspectives. 
The sample interview questions were designed to elicit information about women’s 
responses to side effects, their decisional needs, the decisional support sought by and 
provided to them, and the series of decisions they have made regarding their OET. Field 
notes were recorded during and after the interview focusing on the tenor of the 
discussion and relevant non-verbal cues. All interviews were audio-recorded. 
Compensation 
All participants received a $35 gift card in recognition of their time and effort. 
1.5 Analysis 
Data management 
  Each participant was assigned a unique study identification number to help 
maintain confidentiality. Contact information (participant names, addresses, phone 
numbers, and emails) was collected via voicemail or email and stored in separate 
electronic files. Demographic and treatment information form data was entered into a 
secure, limited access, password protected database. Data entry was verified at least 7 
days after initial data collection. A professional transcriptionist employed as an approved 
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vendor for the university transcribed each recorded interview verbatim. Accuracy of each 
transcript was verified by reading each transcript while listening to the recorded 
interview. Corrections were made as necessary and transcripts were de-identified by 
removing any identifying names. Transcripts, surveys, field notes, and memos were 
stored in a locked file cabinet in a locked private office (paper copies) and on a limited 
access folder on a limited access and password-protected university server (electronic 
copies).  
Quantitative analysis 
All demographic and treatment data were examined for out-of-range values. 
Questionable or outlying values were verified with original documents. Sample 
characteristics were described using descriptive statistics appropriate for the level of 
measurement (e.g., means, standard deviations, frequencies, and percentages) using 
SPSS™ version 21 (IBM, Armonk, NY).  
Qualitative analysis 
When conducting the analyses, decisions were made to combine the analysis of 
Aim 1 with Aim 4 and Aim 2 with Aim 3. Details of the qualitative analysis methods are 
presented in Chapter 2 (for Aims 1 and 4) and in Chapter 3 (for Aims 2 and 3). The final 
products of the analysis therefore included types of responses to side effects, common 
decisional needs, and common decisional supports as well as a framework of the 
experience of OET over time in women who experienced side effects. 
Conclusions 
The framework developed from this study will provide foundational information for 
understanding the experiences of ER+BCS (estrogen receptor positive breast cancer 
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survivors) with OET as it unfolds over time. This information will ultimately be useful for 
developing decisional support materials aimed at meeting decisional needs and 
improving decisional quality. Decisional support materials may include health messages 
about the importance of continued OET, or include a decisional support tool that 
addresses the problem (side effects from OET), alternatives, benefits, and risks related 
to deciding whether to take or not to take prescribed therapies. As a result of continued 
work in this area, there may be better congruence between a woman’s decisional needs 
and the decisional support she receives. 
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Chapter 2 
This chapter presents the results of a systematic review that examined literature 
pertaining to OET non-adherence and side effects using the Ottawa Decision Support 
Framework (ODSF) categories of decisional supports and decisional needs as requisites 
for quality decision making.  
2.1 Introduction 
Oral endocrine therapy (OET) is standard therapy for estrogen receptor-positive 
(ER+) breast cancer.2.1 An estimated 75% of women with breast cancer receive a 
recommendation for life-saving OET such as tamoxifen or aromatase inhibitors.2.11 OET 
is prescribed for ER+ breast cancer to prevent recurrence by blocking certain hormones 
that fuel cancer growth.  
The approach to OET in breast cancer survivors (BCS) with ER+ breast cancer 
depends on whether or not a woman is in menopause.  Tamoxifen is prescribed to pre-, 
peri-, or post-menopausal women and has been shown to decrease breast cancer 
recurrence by 41% and mortality by 34%.2.2,2.3 Aromatase inhibitors (AIs), prescribed 
only for postmenopausal women, have been shown to reduce recurrence by 30-41% 
and metastasis by 16-18%, with mortality rate reductions similar to tamoxifen.2.2,2.3,2.4As a 
class, the AIs have consistently been shown to improve outcomes for postmenopausal 
women with hormone receptor-positive breast cancer compared with tamoxifen.2.44 Each 
AI agent is taken on a daily basis for the duration of a minimum of 5 years, and 
sometimes longer. 
Despite the benefits of OET for BCS diagnosed with ER+ breast cancer, many 
BCS decide not to take their OET as recommended.2.7-2.9,2.13,1.17,2.30The decision to take 
OET is not a single event decision, but a complex process that occurs over time as a 
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series of one time daily decisions or twice daily decisions. Studies show that 30-50% of 
BCS who initiate therapy are not adherent to daily or twice-daily pill ingestion, and 
alarmingly 70% prematurely stop the therapy before the end of the once recommended 
5-year period.2.2,2.3More recently, trials have suggested that 10 years of tamoxifen 
treatment is better than 5 years and that a program of extended adjuvant therapy of 
tamoxifen for 5 years followed by AI for 5 more years is effective for suitable 
candidates.2.4  This new recommendation causes more concern regarding the 70% early 
termination rates seen with a 5 year course of therapy. 
Understanding BCS’s decisional supports (e.g. any support given to meet an 
identified decisional need) and decisional needs (e.g. any need a person may have that 
makes it difficult to make a quality decision) is important to help facilitate adherence to 
OET, particularly when side effects are experienced.2.15 Tamoxifen side effects include 
hot flashes, weight gain, and loss of libido, and less commonly thromboembolic disease 
or endometrial pathologies.2.4-2.  Side effects of AI include hot flashes, arthralgia, 
increased fractures, rash, and gastrointestinal upset.2.5,2.5,2.10-2.14 Understanding the 
decisional needs and support is a first step in creating a patient centered intervention to 
increase the percentage of BCS that correctly use this potentially life-saving treatment. 
2.2 Purpose and Aims 
The purpose of this review was to examine literature pertaining to OET non-
adherence and side effects using the Ottawa Decision Support Framework (ODSF) 
categories of decisional supports and decisional needs as requisites for quality decision 
making. Study aims were to use the available literature to summarize the following: (1) 
general nature of the studies, (2) link between incidence of non-adherence and side 
effects, (3) details of BCS’s decisional supports, and (4) thematic categories of BCS’s 
unmet decisional needs.  
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2.3 Conceptual Framework 
The ODSF was the conceptual framework for this study. The framework 
suggests that quality decisions result when decisional needs (e.g. knowledge, 
expectations, values) are understood and appropriate decisional supports (e.g. 
coaching, counseling, providing facts and probabilities) are provided.2.15 Decisional 
support is defined as any support that is given to meet an identified decisional need. 2.15  
The goal of decisional support is to address modifiable determinants of decision making 
that are suboptimal. These determinants can include inadequate knowledge, unrealistic 
expectations, unclear values, unclear norms, unwanted pressure, inadequate support, 
and inadequate personal and external resources to make the decision.2.4,2.15,2.16 
Decisional needs are defined as any need a person may have that makes it difficult to 
make a decision.2.15 Decisional needs are based on the knowledge, degree of certainty, 
expectations, and values one may have regarding the decision to be made.2.15,2.16  
2.4 Methods and Search Strategy 
A systematic literature search was performed in PubMed and CINAHL. The 
PubMed database was selected because biomedical topics and the sciences are the 
primary foci of articles contained in this database, and the content areas directly relate to 
the topic for this review. In addition, PubMed includes all articles indexed in 
MEDLINE.2.37 CINAHL was selected instead of OVID for its coverage of full-text nursing 
medical journals published by many different publishers. OVID searches are limited to 
articles published only by OVID and its publishing partners.2.38 Only peer reviewed 
articles were included in the review so PROQUEST or other dissertation search engines 
were not included. The search strategy for PubMED and CINAHL databases combined 
the search terms “aromatase inhibitors and adherence” and “tamoxifen and adherence.” 
In order to maximize inclusion, study type and publication date were not limited in the 
search strategy and articles including all factors associated with OET non-adherence 
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(not just side effects as a single factor) were included. In addition, reference lists of 
identified review articles were manually searched to identify potentially relevant 
additional articles. First, titles and abstracts were screened. Second, the full texts of all 
potentially relevant articles were obtained and read to determine suitability for inclusion. 
Articles were identified for inclusion by the primary author (PhD candidate) according to 
predetermined criteria and then verified by a second reviewer.  
Inclusion and exclusion criteria 
To be eligible for this review, manuscripts had to meet the following inclusion 
criteria: (1) study population of adult females with a diagnosis of breast cancer, (2) intake 
of tamoxifen or AIs, (3) quantitative or qualitative analyses between medication and 
adherence (e.g. reported side effects attributed to non-adherence), and (4) full-length, 
original research. All types and stages of breast cancer were included. Articles that were 
excluded were: (1) in non-English language, (2) focused solely on reporting adherence 
rates and not including factors contributing to non-adherence, (3) reviews, or (4) 
editorials, opinion papers, or abstracts. 
Data extraction 
Data were extracted and organized into 4 separate tables, which are described 
below. All extracted data were verified by a second reviewer. Table 2.1 shows a general 
overview of the study characteristics including author, publication year, country where 
the study was conducted, study design, length of study, cancer stage of participants, 
sample size, and the class of medication (tamoxifen or AI). Table 2.2 focuses on the 
rates of non-adherence to the OET assessed in each study, the prevalence of side 
effects reported, and whether or not side effects were reported as a reason for non-
adherence. Data extracted into Table 2.3 focused on decisional support participants 
reportedly received when receiving the OET prescription or at follow-up visits during the 
recommended treatment. Using categories from the ODSF, the table delineates the type, 
24 
source, timing, and content of provided support. Table 2.4 focuses on decisional needs. 
Identified needs are grouped according to four thematic categories that emerged from 
the available data within the articles: (1) regimen (not understanding timing, dose, or 
duration of OET), (2) beliefs about benefits and risks (OET being unhelpful, not 
necessary, or other negative or neutral beliefs about OET), (3) inadequate information 
(insufficient or confusing information, inadequate knowledge of side effects, or 
inadequate knowledge of tumor hormone status), and (4) having no one to ask questions 
to (inadequate support to gather information). For studies that contained no detailed 
information, decisional needs were marked as “not reported.”  
2.5 Results 
The search in the PubMed electronic database yielded 222 articles. After title and 
abstract screening, 99 articles were identified as potentially relevant. After removing 18 
duplicates, 81 full-text versions were screened in detail. Finally, 24 studies were included 
based on the inclusion and exclusion criteria. The search in the CINAHL electronic 
database yielded 98 articles. After title and abstract screening, 24 articles that were 
duplicated in the PubMed were excluded and 6 articles were screened in detail. Finally, 
one additional article from the CINAHL search was included in the review. The manual 
search and reference check revealed no further relevant publications. The flowchart in 
Figure 2.1 illustrates the selection process. 
Characteristics of studies  
 The characteristics of identified studies are summarized in Table 2.1. Most 
articles were published after 2012 (n=13, 54.0%), 2.5,2.6,2.10-2.14,2.17-2.22,2.36with publication 
dates ranging from 2001-2014. Many studies were conducted in the United States 
(n=12, 48.0%),2.5-2.7,2.9,2.12-2.14,2.21,2.23-2.25 used quantitative methods, and reported on data 
collected using standardized self-report measures. Duration of study time points varied 
from a single one-time mailing to 12 years, but not all studies reported this information. 
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Stage of breast cancer ranged from 0-IV with not all studies reporting this information. 
Sample sizes ranged from 30 BCS to 1,531 online posts by BCS. Participant ages 
ranged from 18 to >85. Class of OET studied was fairly well distributed across the 
relevant literature with 9 studies (36.0%) including both types of OET, 9 studies (37.5%) 
reporting on tamoxifen, and 7 studies (29.1%) reporting on AIs. 
Prevalence of non-adherence and side effects  
As shown in Table 2.2, non-adherence rates to tamoxifen ranged from 7.3% to 
54.0% and to AI it ranged from 5.8% to 61.0%. Studies also reported 3.0-58.0% non-
adherence rates to overall therapy and not individually by drug adherence rates.  
As shown in Table 2.2, Tamoxifen side effect prevalence ranged from 8.0-66.7% 
and AI side effect prevalence ranged from 18.2-66.7%. In studies that reported 
prevalence to overall therapy and not individually by drug, side effect prevalence rates 
ranged from 3.0-69.8%. Four studies did not provide side effect prevalence rates but did 
include narrative description of the impact of experiencing side effects on adherence to 
OET. 
Side effects were a reason for non-adherence in 23 out of 25 (92.0%) identified 
studies. Studies that focused on both tamoxifen and AIs often did not report side effects 
by drug. Four studies (16.0%) did not include information on specific side effects 
experienced. In addition, 1 study (4.2%) measured only severity and not the type of side 
effects, 2 studies (8.3%) were specific to a single side effect, and 1 study (4.2%) 
reported the general experience of side effects. Hot flashes were described in 13 studies 
(54.2%), joint pains in 8 studies (33.3%), fatigue/loss of energy in 7 studies (29.2%), 
mood problems in 6 studies (25.0%), sexual dysfunction in 5 studies (20.8%), night 
sweats in 4 studies (16.7%), and sleep problems in 2 studies (8.3%). 
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Decisional supports  
Details on decisional support were absent in 13 (52.0%) of the identified studies, 
either because decisional support was not assessed or was not reported as part of the 
results. As shown in Table 2.3, types and sources of decisional support included verbal 
information from providers as well as print or media (internet, magazines, television, 
books). The time when decisional support was provided or sought by BCS was 
commonly reported as following initial prescription, but some articles also alluded to 
support being provided prior to initial prescription and also at follow-up visits. Message 
content was not always described within the articles. In 4 other studies (16.7%), 
information was limited to side effects only. In addition, in 4 studies (16.7%), participants 
specifically described the information they received as being insufficient. Only 1 study 
(4.2%) included information that BCS were informed of the importance of taking OET at 
almost every visit and had the opportunity to discuss side effects with their provider. 
Decisional needs 
Decisional needs are summarized in Table 2.4. Decisional needs were not 
consistently assessed or reported, with 10 studies (40.0%) not reporting any information 
on decisional needs of BCS experiencing side effects from OET. In the remaining 15 
studies (62.5%), the most common categories of decisional needs were inadequate 
information (n=7 studies). One study described anxiety and uncertainty in BCS regarding 
their symptom experience, especially when physicians could not explain the exact 
etiology of their symptoms.2.26 Another study included data about BCS not having 
anyone to ask questions to and not understanding the duration, timing, or dose of their 
medication or having anyone available to answer questions.2.18  
2.6 Discussion 
In addition to providing a summary of the general nature of the studies that have 
been conducted on OET non-adherence in BCS who are experiencing side effects, there 
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are 3 main findings resulting from this review. First, the review summarizes evidence of 
the relationship between the experience of having side effects and OET non-adherence. 
Second, this review demonstrates the absence of decisional supports provided or 
available to BCS who are experiencing OET side effects. Third, this review 
demonstrates BCS have unmet decisional needs in their OET side effect-related 
decision-making processes. Each of these findings is discussed in detail below. 
Relationship between non-adherence and side effects 
The relationship between OET non-adherence and side effects underscores the 
importance of this clinical problem and provides evidence supporting the widespread 
notion that OET side effects are a major reason for non-adherence. Reported non-
adherence rates are thought to be dependent on a range of parameters, including 
whether the patients are participating in a clinical trial, the period since initiating 
treatment, and methods used to assess adherence and medication use.2.27 It is likely that 
rates of non-adherence varied within these studies for similar reasons. Regardless of 
rates, non-adherence was primarily attributed to the experience of side effects. Within 
this literature, women who reported experiencing OET side effects were two to four 
times more likely to discontinue OET earlier than five years,2.5-2.9 and women who 
reported severe side effects were five times more likely to discontinue therapy earlier 
than five years.2.10 Although side effects caused women to switch to a different OET, 
switching did not prevent further side effects and many women subsequently 
discontinued even the second OET.2.11 
Methods used to assess side effects of OET varied. Side effects were not 
assessed using comprehensive self-report measures, which interfere with understanding 
the true experience of the effect of these drugs. In addition, side effects were reported 
from overall OET, limiting our full understanding of side effects experienced by the drug. 
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Regardless, our review findings suggest that future research should be focused on 
improved understanding and elimination of non-adherence caused by side effects.   
Absence of decisional supports 
A second major finding of this review was the absence and inadequacy of 
available decisional supports for this population. The most frequently endorsed source of 
informational support was verbal direction from the provider occurring at the time of OET 
prescription. Details about existing support were limited, but when support was available, 
it was aimed mostly at the potential experience of side effects. Current support seemed 
to be lacking the side effect management strategies or stressing the importance of 
remaining on a regimen even when experiencing side effects. 
Even when BCS reported receiving support, they reported that it was inadequate. 
BCS reported that they were not given understandable OET-related information. The 
information they did receive was not sufficient, and they did not have the opportunity to 
ask questions. Limiting support only to information and not considering additional 
determinants of decision making such as unrealistic expectations, unclear values, 
unclear norms, or inadequate personal and external resources increases the potential 
for poor quality decisions.2.16 
The absence of decisional support may be partially due to the lack of decisional 
support tools for this population. Decisional support tools often come in the form of a 
decision aid, which is an intervention that helps patients make specific and deliberate 
choices among options. Decision aids often provide information on treatment options 
and outcomes relevant to a person’s health status, and they include methods to clarify 
patients’ values.2.28 The Patient Decision Aids Research Group, affiliated with the Ottawa 
Hospital Research Institute, is an international research team that designs and tests 
decision aids and decisional support training programs for patients and health 
practitioners. The group manages a database of decision aids that can be uploaded and 
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shared if they adhere to established guidelines, provided  that they (1) meet the 
definition of a decision aid, (2) are not more than 5 years old, (3) provide references to 
scientific evidence, and (4) are publicly available.2.15 When the authors searched this 
database for decision aids that would support the OET decision-making process, only 
one tool was found. This decisional support tool is a decision aid for OET that focuses 
only on post-menopausal BCS making the initial decision to initiate therapy and does not 
take into consideration OET side effects or decision making as a process unfolding over 
time, which can last 5-10 years.2.29 This further shows that there are inadequate 
resources for patients and providers to address the side effects and resulting impact on 
adherence to OET. 
Unmet decisional needs  
More importantly, this review showed that decisional needs are not 
systematically assessed in research or clinical practice. Assessment of decisional needs 
is important in decision making because it can identify what is important for the decision 
making, as well as what could be done better in the form of effective decisional 
support.2.15 
A revealing finding from this review was the influence of beliefs about OET on 
adherence. BCS held complex beliefs about their OET, and for a number of BCS the 
decision to discontinue OET seemed to be the result of rational but misguided beliefs 
about their experience of side effects.2.30 Attempting to address their unmet decisional 
needs through seeking inaccurate information likely contributed to the formation of 
inaccurate beliefs about OET. This finding is important for adherence because it has 
been shown that BCS with negative or neutral beliefs about the value of OET were more 
likely to discontinue it.2.7 BCS report having unmet needs regarding information they 
receive, and they report seeking additional information from sources other than their 
provider. Although BCS turn to alternative sources for OET-related information, these 
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sources may not provide adequate benefit due to the uneven quality, conflicting claims, 
redundancy, and difficulties associated with assessing information accuracy and 
applicability.2.31  
2.7 Limitations 
Review findings should be interpreted in light of some limitations. First, 
information on needs and support had to be extracted from methods and results 
sections. Thus, our findings may actually under-represent BCS’s supports and needs, 
suggesting that a more detailed and purposeful study of supports and needs is 
warranted. A logical next step for research would be to conduct a detailed, basic, 
descriptive study of BCS’s decision-making processes and the unfolding of their 
decisional needs and supports over time. Second, the literature search was limited to 
English language articles. Search limitations could have limited the search results and 
potentially omitted additional findings published in other languages or identified in less 
popular journals not indexed within PubMed or CINAHL.   
2.8 Conclusions 
Overall, the prevalence of side effects was quite high and was cited as the major 
reason for discontinuing OET. Our study confirms that non-adherence to OET due to the 
experience of side effects remains an importance issue, primarily because BCS 
experiencing OET side effects have unmet decisional needs and lack adequate 
decisional supports. 
This review indicates that more decisional support for BCS experiencing side 
effects related to OET may be needed. Although we know that side effects contribute to 
BCS's decisions to stop OET, we do not understand the details of the process or how 
that process may contribute to decision making. In addition, although we know that BCS 
state that they receive insufficient information about side effects from providers and seek 
out additional information, we do not fully understand that process or how it may relate to 
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decision making. Future research is needed to further define the concepts of decisional 
needs and decisional supports for BCS experiencing side effects from OET in order to 
develop patient-centered materials to improve outcomes of OET therapy. Narrative 
accounts by BCS who are experiencing OET side effects will provide foundational 
descriptive information needed to generate interventions to improve quality decision 
making, such as a decision aid. In order to address the gap in currently available 
decision aids, next steps should include qualitative descriptive research to generate a 
full understanding of the decision-making process in BCS who experience OET side 
effects.  
2.9 Implications for practice 
 This review generates some insights for providers who treat BCS with OETs, 
particularly when they are assessing OET adherence and side effects. The decision to 
take OET is not a single event decision, but a complex social process that occurs over 
time as a series of one time daily decisions or twice daily decisions over the course of up 
to 10 years. This decision making is further complicated for BCS who experience side 
effects. Categories of side effects, adherence, decisional support, and decisional needs 
are all associated with OET decision making, and each of these categories is associated 
with specific clinical implications as discussed below. 
At some point during OET treatment, a large proportion of BCS are likely to 
experience some type of side effect.2.5-2.7,2.10-2.12,2.17-2.20,2.23-2.26,2.30,2.32-2.35 Inadequately 
managed side effects potentially increase non-adherence, leading to an increased risk of 
breast cancer recurrence.2.2,2.3 Current methods to assess side effects are inconsistent 
and unstandardized across the research literature.2.36 Existing literature suggests that 
providers are failing to document the assessment of side effects. Furthermore, this 
review indicates that little is known about how information regarding side effects is 
communicated. Clinician recorded side effects tend to emphasize serious, life-
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threatening adverse events rather than patient-reported issues affecting quality of life. 
Information communicated to women by providers may not fully encompass the true side 
effect burden that may result from OET. Poor or inadequate communication fuels lack of 
understanding, which can further negatively impact clinicians’ abilities to support BCS in 
the management of their side effects and poor quality decisions made by BCS regarding 
their OET. We recommend that provider assessments include patient report of the 
experience of side effects from OET at every clinical visit as well as an assessment of 
adherence.  
Decisional support for BCS can be provided in several different ways. Decisional 
support from providers may include health messages about the importance of continued 
OET or include a decisional support tool that addresses the problem (side effects from 
OET), alternatives, benefits, and risks related to whether or not to take prescribed 
therapies. By providing decisional support to BCS using these methods, unmet 
decisional needs may be minimized, leading to a quality decision. Results of this review 
suggest that the lack of decisional support for BCS may lead to unmet decisional needs 
and provide a basis to guide health provider encounters with BCS taking OET.  
According to the ODSF, the primary driver of individuals able to make quality 
decisions is based on whether their decisional needs are understood and supported.2.15 
BCS who are inadequately informed about OET side effects or the importance of 
adherence are likely to have unmet decisional needs. By identifying unmet decisional 
needs, health providers can then be guided towards the types of patient centered OET 
health information BCS need in order to have adequate support. Providers can 
determine unmet decisional needs and tailor decisional support provided to BCS during 
patient encounters resulting in quality decisions that lead to side effect management 
ultimately resulting in improved adherence to OET. 
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Figure 2.1: Information Sources  
 
  
Relevent literature identified 
through search terms 
PubMed (n=222) 
CINAHL (n=98) 
Excluded after abstract 
screening 
PubMed (n=127) 
CINAHL (n=68) 
Potentially eligible after 
abstract screening  
PubMed(n=99) 
CINAHL (n=30) 
 
Excluded after full-text screening 
 
PubMed                                                                                                      
Reasons for exclusion:                                                                                                                    
*Case study (n=1) 
* Review Article (n=12)                                                  
* Limited to only measuring adherence 
(n=5)           
* Establishing Clinical Guidelines 
(n=32) 
* Full-text Non-English (n=6) 
* Duplicates(n=18) 
 
CINAHL 
Reasons for exclusion: 
*Case study (n=1) 
*Review Article (n=4) 
* Duplicates to PubMed Search  
 
Relevent studies (n=25) 
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Table 2.1: Study Characteristics 
Author, 
year, 
country 
Study Design and Length 
Sample Medication 
Stage N TAM AI 
Aiello 
Bowles et 
al., 2012, 
USA 
Cross-sectional survey 3 mos. 1,2 538 X X 
Atkins & 
Fallowfield, 
2006, UK 
Cross-sectional survey NR 
 
131 X X 
Bell et al., 
2013, 
Australia 
Prospective 
longitudinal survey 
4 yrs. 1,>1 1193 X X 
Boonstra et 
al., 2013, 
Netherlands 
Cross-sectional 
observational study 
3 mos. 1,2,3 57 
 
X 
Bramwell et 
al., 2009, 
Canada 
Randomized , 
placebo-controlled trial 
12 yrs. 1,2,3 672 X 
 
Chim et al., 
2013, USA 
Cross-sectional survey 
18 
mos. 
1,2,3 437 
 
X 
Cluz et al., 
2012, 
France 
Prospective 
longitudinal survey 
3.5 
yrs. 
1,2,3 196 x 
 
Demissie et 
al.,  2001, 
USA 
Prospective 
longitudinal survey 
3 yrs. 1,2 292 X 
 
Fink et al., 
2004, USA 
Prospective 
longitudinal survey 
3 yrs. 1,2,3a 597 X 
 
Grunfield, 
2005, UK 
Cross-sectional survey NR NR 110 X 
 
Harrow, A. 
et al., 2014, 
UK 
Qualitative semi-
structured  interviews 
6 mos. NR 30 X X 
Henry et al., 
2012, USA 
Randomized clinical 
trial 
4 yrs. 0,1,2,3 503 
 
X 
Kahn et al., 
2007, USA 
Prospective Cohort 
Study 
4 yrs. 1,2,3 881 X 
 
Kemp, 
2014, 
Australia 
Observational 5 yrs. All 1531 X X 
Kirk & 
Hudis, 
2008, USA 
Online survey 6 yrs. All 328 X X 
Kyvernitakis 
et al., 2014, 
Germany 
Randomized clinical 
trial 
2 yrs. 1,2,3 180 
 
X 
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Lash et al., 
2006, USA 
Prospective 
longitudinal survey 
3 yrs. I,2,3a 462 X 
 
Mao et al., 
2013, USA 
Content analysis NR All 
25256 
posts  
X 
Oberguggen
berger et 
al., 2011, 
Austria 
Cross-sectional survey 5 yrs. 1,2,3 280 
 
X 
Owusu et 
al., 2011, 
USA 
Prospective cohort 
study 
5 yrs. 1-2b 961 X 
 
Pellegrini et 
al., 2010, 
France 
Qualitative Grounded 
theory study 
NR NR 34 X 
 
Schover et 
al., 2014, 
USA 
Cross-sectional survey 
single 
mailed 
survey 
1-2a 129 
 
X 
Simon et al., 
2014, 
Canada 
Cross-sectional survey 6 mos. 0-4 161 X X 
Stanton, 
Petrie & 
Partridge, 
2014, USA 
Cross-sectional survey 
2 
weeks 
0-4 1465 X X 
Wouters et 
al., 2013, 
Netherlands 
Qualitative  Focus 
Groups and individual 
interviews 
<1 
year 
post-
OET 
comple
tion 
NR 37 X X 
Abbreviations: NR, not reported; yrs., years; mos., months; OET, oral endocrine therapy; 
X, medication included in study TAM, Tamoxifan; AI, Aromatase Inhibitor. 
Stage is cancer stage.  
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Table 2.2: Side Effects  
Authors 
Prevalence of Non 
Adherence 
(stopping OET prior to 5 
years)  
Prevalence of Side 
Effects 
Side Effect 
Noted as 
Reason for 
Non-
adherence 
  TAM AI Both TAM AI   
Aiello Bowles et 
al.  
43.9% 
(n=43) 
22.4% 
(n=22) 
33.7%  
(n=33) 
66.70% 
(n=32) 
59.10% 
(n=39)  
X 
  
Atkins & 
Fallowfield   
54% 
(n=39) 
61% 
(n=22)  
  NR NR X 
Bell et al.  
7.30% 
n=88 
5.80% 
n=69 
NR a a X 
Boonstra et al.     31%     74% NR 
Bramwell et al   
26% 
(n=173) 
    
8% 
(n=29) 
  X 
Chim et al.   
  
  
11% 
(n=47) 
    
82% 
(n=358) 
X 
Cluze et al.   
40% 
(n=27) 
42% 
(n=5)aa 
  
47% 
(n=92) 
aa X 
Demissie et al.   
15% 
(n=26) 
    
63% 
(n=104) 
  X 
Fink et al.  
17% 
(n=88) 
    
45% 
(n=271) 
  NR 
Grunfield    
13% 
(n=13) 
    
46% 
(n=6) 
  X 
Henry et al.    
43% 
(n=216) 
      
33% 
(n=163) 
X 
Kahn et al.    
 
21% 
(n=185) 
    
21% 
(n=185) 
  X 
Kemp   
58% 
(n=888) 
NR  X 
Kirk & Hudis   NR NR 
17% 
(n=53) 
69.80% 
(n=37) 
X 
Kyvernitakis et al.   
22% 
(n=40) 
    
100% 
(n=159) 
X 
Lash et al. 
31% 
(n=143) 
    
49% 
(n=227) 
  X 
Mao et al.   
13% 
(n=110) 
  
18.2% 
(n=4,596 
posts) 
  X 
Owusu et al. 
46% 
(n=442) 
  NR  X 
Oberguggenberger 
et al. 
 NR   
59.6% 
(n=167) 
X 
Schover et al.   
15.5% 
(n=20) 
    
79% 
(n=53) 
X 
Stanton, Petrie, & 
Partridge 
    
3% 
(n=44) 
48% 
(n=326) 
X 
37 
Harrow, A. et al.   
10% 
(n=3) 
NR NR X 
Mao et al.  
13% 
(n=110) 
  
18.2% 
(n=4,59
6 posts) 
X 
Pellegrini et al. 
18% 
(n=6) 
  
NR   X 
Simon et al. NR NR 
6% 
(n=7) 
6% (n=7) 
X 
 
Wouters et al.   
19% 
(n=7) 
NR NR X 
Abbreviations: NR, not reported; TAM, tamoxifen; AI, aromatase inhibitor; X, side effect 
noted as reason  
for non-adherence, empty boxes indicate information not available. 
asome BCS reported more than one side effect, some reported none. All answers were 
included; prevalence could not be determined. 
aaRates of interruption of AI reported on larger cohort sample not included in analyses. 
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Table 2.3: Decisional Support 
Details Contained in Articles on the Type, Source, Timing, and Content of 
Messages Given for Decisional Support 
Author(s) Type Source Timing Message Content 
Aiello Bowles et al. * * * * 
Atkins & 
Fallowfield 
* * * * 
Bell et al. Verbal Provider Following 
RX 
* 
Boonstra et al. Verbal Provider Prior to 
RX and at 
follow-up 
Side effects information 
Bramwell et al * * * * 
Chim et al. * * * * 
Cluz et al. Verbal Provider Following 
RX 
BCS reported they were not 
given understandable OET-
related information 
BCS reported they did not 
consider their information 
sufficient 
BCS reported they did not have 
the opportunity to ask questions 
at diagnosis  
Demissie et al.  Print, 
media, 
verbal 
Books 
Magazines 
Television 
Provider 
Following 
RX 
* 
Fink et al. * * * * 
Grunfield * * * * 
Harrow, A. et al. Print, 
media, 
verbal 
Internet 
Provider 
Following 
RX 
Even though given side effects 
information, BCS reported not 
being asked whether or not 
they were still taking the 
medication at follow-up visits 
Henry et al. * * * * 
Kahn et al.  Verbal Provider Following 
RX 
BCS reported not receiving 
information about side effects in 
advance from their provider 
BCS reported not receiving 
adequate information from their 
provider 
Kemp * * * * 
Kirk & Hudis,  Verbal Provider Following 
RX and at 
follow-up 
visits 
BCS told importance of taking 
OETs at almost every visit 
BCS discussed side effects 
with provider 
Kyvernitakis et al. * * * * 
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Lash et al. * * * * 
Mao et al.  Media Internet 
message 
boards 
Not 
specified 
Side effects information 
Oberguggenberger 
et al. * * * * 
Owusu et al.  * * * * 
Pellegrini et al. Print, 
media, 
verbal 
Peers, 
Provider 
Internet 
Following 
RX 
Side effects information 
described OET as hormone or 
anti-hormone 
Schover et al. Verbal Provider Following 
RX 
Side effects information 
Simon et al. * * * * 
Stanton, Petrie, & 
Partridge 
* * * * 
Wouters et al. Verbal Provider Following 
RX 
Side effects information 
provided 
BCS reported they were not 
given information that taking 
OET at the same time every 
day was important 
BCS reported that the duration 
of therapy was unclear 
Abbreviations: RX, Prescription; *, no relevant information available in article. 
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Abbreviations: X = article described unmet decisional needs within this category. 
 
 
 
 
Table 2.4:  Decisional Needs 
 
Author 
Regimen 
(timing, 
dose, 
duration) 
Beliefs 
of 
Benefits 
& Risks 
Inadequate 
Information 
No One to 
Ask 
Questions 
No 
Information 
Reported 
Aiello Bowles et 
al.  
X 
   
Atkins & 
Fallowfield     
X 
Bell et al. 
  
X 
  
Boonstra et al. 
  
X 
  
Bramwell et al 
    
X 
Chim et al. 
    
X 
Cluz et al. 
     
Demissie et al. 
 
X 
   
Fink et al. 
 
X 
   
Grunfield 
 
X 
   
Harrow, A. et al. 
   
X 
 
Henry et al. 
    
X 
Kahn et al. 
  
X 
  
Kemp 
    
X 
Kirk & Hudis, 
 
X 
   
Kyvernitakis et 
al.     
X 
Lash et al. 
    
X 
Mao et al. 
    
X 
Oberguggenber
ger et al.     
X 
Owusu et al. 
  
X 
  
Pellegrini et al. 
  
X 
  
Schover et al. 
  
X 
  
Simon et al.     X 
Stanton, Petrie, 
& Partridge  
X 
   
Wouters et al. X 
 
X 
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Chapter 3 
 This chapter presents an exploratory framework depicting the process through 
which women’s experiences unfold over time. 
3.1 Introduction 
 About 75% of all breast cancer diagnoses are estrogen receptor positive 
(ER+BC).3.1 Women diagnosed with ER+BC receive a prescription for oral endocrine 
therapy (OET), which prevents breast cancer recurrence by blocking certain hormones 
that fuel cancer growth. Examples of OET are tamoxifen and a class of medications 
called aromatase inhibitors (AIs, e.g., anastrazole, Letrozole, or exemestane). 
Tamoxifen decreases breast cancer recurrence by 41% and mortality by 34%, whereas 
AIs reduce recurrence by 30-41% and metastasis by 16-18%.3.8 
  Despite the benefits of OET, many women diagnosed with ER+BC do not take it 
as recommended, often due to its adverse side effects.3.3 Common side effects, which 
include hot flashes, sleep disturbances, muscle aches and pains, and difficulty 
concentrating, are difficult for women to endure, especially because OET is currently 
recommended for five or more years.7 
 The OET experience is a complex process that evolves over time and frequently 
involves dealing with troubling side effects. Understanding women’s experience of OET 
can provide a foundation for developing strategies to support women taking OET. 
However, studies on women’s experience with OET are limited. The purpose of this 
study, therefore, was to develop a theoretical framework that depicts the process 
through which women’s experiences with OET unfold over time. 
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3.2 Methods 
Design  
 Grounded theory, a method of qualitative inquiry used to construct theory through 
rigorous analysis of data, was used in this study.3.4 Grounded theory focuses on the 
complexities of people undergoing change, the influence of social interactions and social 
context on the phenomenon of interest, critical junctures in psychosocial processes, and 
the description of responses of people sharing a common challenge.3.4 We chose 
grounded theory for this study because women with ER+BC who are prescribed OET 
and experience side effects share a common challenge and respond to this challenge 
through a complex process that changes over time and occurs in the sociocultural 
context of breast cancer treatment practices.  
Sample 
 Women who were diagnosed with ER+BC, prescribed OET, and had 
experienced side effects from the OET comprised the sample.  Additional inclusion 
criteria were (1) age 40 to 75 years, (2) first time diagnosis of ER+BC, (3) completion of 
primary therapy, (4) receipt of OET prescription 6-24 months prior to interview, and (5) 
the ability to read, speak, and understand English. The age limit controlled for 
childbearing and possible age-induced cognitive changes, first time diagnosis avoided 
patients with previous OET recommendations, and the 6-24 months timeframe allowed 
patients to experience side effects and respond to them by switching or discontinuing 
OET. Exclusion criteria included having (1) a health proxy or guardian that made 
decisions on the patients’ behalf, (2) a current or previous diagnosis of a serious mental 
disorder such as psychosis or dementia, or (3) a poor recall of OET experience. 
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Recruitment  
 The study was approved by the appropriate Institutional Review Board and 
Scientific Review Committees. Potential participants were recruited with several 
strategies. First, study fliers were placed where women diagnosed with breast cancer 
were likely to frequent, such as clinic waiting rooms. Second, a Facebook study page 
was shared with breast cancer groups and Facebook paid advertising notified potentially 
eligible women for the study. Third, local agencies that supported minority BCS emailed 
study notifications to local women. Fourth, study invitations were mailed to potential 
eligible women identified through clinic- and registry-based databases. Women were 
invited to correspond with the research team via telephone or email if they were 
interested in participation in the study.  
 The research team conducted telephone screenings to determine if potential 
participants met inclusion criteria. Fifty-three women telephoned the author (PhD 
candidate) to express interest but two could not be contacted again. Among the 
remaining 51 women, 17 (33%) were not eligible because they had previous diagnosis of 
breast cancer (n=3), were not ER+ (n=1), received initial OET prescription greater than 
24 months ago (n=4), had no side effects (n=5), did not initiate OET (n=3), and were still 
receiving primary therapy (n=1). The remaining 34 women completed the interview but 
three were ineligible due the lack of side effects (n=1) or previous diagnosis of breast 
cancer (n=2). The final sample of 31 participants represented 58% of the initial pool of 
women who expressed interest in the study.  
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Data collection  
 After obtaining consent, the researchers interviewed participants in a semi-
structured interview using the interview guide created by the research team. It began 
with the question:  
“Think back to when you first became aware that the tamoxifen or 
aromatase inhibitors would be part of your treatment for breast cancer. 
Tell me as much as you can about this time, including where the 
information came from, what type of information you received, and 
whether or not you were informed about potential side effects.”  
The team then asked more structured questions about the participants’ experiences with 
OET, side effects, and their needs and supports for making decisions about OET. Upon 
completion of the interview, participants created a timeline to validate the chronology of 
events discussed. Participants received a $35 dollar gift card to compensate for their 
time. Interviews were audio-recorded and transcribed by a professional transcriptionist.  
3.3 Data Analysis  
 Data analysis began as soon as the first interview was transcribed and verified.  
All three authors (nurse scientists) were involved in the data analysis. Constant 
comparative analysis was used to discover common patterns and variation in the data, 
and grounded theory coding principles were followed (Charmaz, 2006).3.2 The 
procedures included initial, focused, axial, and theoretical coding (Charmaz, 2006).3.2 
Initial coding, which is the labeling of all important facts and ideas in the transcripts, was 
conducted by the first author and verified by the others. Focused coding is the 
examination of initial codes for the presence of significant or recurring codes that are 
then grouped together to form categories. The first author proposed potential categories 
that were reviewed, discussed, and modified by the other authors. Axial coding involves 
returning to the data to define the attributes and characteristics of the generated 
categories, and theoretical coding is the identification of the potential relationships 
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among the generated categories. Theoretical sampling, defined as sampling to collect 
specific information needed to develop categories or enhance the theoretical framework, 
was done during theoretical coding (Charmaz, 2006).3.2 Due to the highly interpretive 
nature of axial and theoretical coding, the authors met biweekly to discuss findings and 
develop the final framework.  
3.4 Results 
Sample  
 The average age of the participants was 55 (SD=8.35, range=42-70 years). 
Twenty-six were White (83.8%), 2 were Hispanic (6.5%), 2 were African American 
(5.5%), and 1 was multi-racial (3.2%). All participants had at least a high school 
education (100%), the majority were employed full-time (51%), and only 2 reported 
difficulty in paying for housing and food (6.4%). Twenty-five participants (80.6%) 
reported taking herbal supplements or vitamins. At the time of the interview, 12 
participants were on original tamoxifen (38.7%), 1 was on tamoxifen after switching from 
AI (3.2%), 8 were on their original AI prescription (25.0%), 2 were now on AI after 
switching from Tamoxifen (6.5%), 3 were on a different AI after switching from another 
AI (9.6%), 4 stopped after original OET and did not switch to another (12.9%),  and 1 
participant stopped after switching OET (3.2%).  
Framework  
 The framework described below reflects a social process through which women’s 
experiences with OET unfolded over time. Commonalities in the participants’ narratives 
suggested that this process included four stages. The authors labeled the four stages as 
follows: being told what I need to do to live, doing what I need to do to live, enduring 
what I need to do to live, and deciding how I want to live.   
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Because the four-stage framework is a conceptual rendering of a common 
process, it does not necessarily capture the full heterogeneity of the participants’ 
experiences. For example, while many of the participants experienced the stages 
chronologically as described below, not all participants experienced each stage, and 
some experienced the stages in a different sequence or for differing lengths of time. The 
framework nonetheless represents a typical trajectory for women who are prescribed 
OET and who experience side effects. 
Being told what I need to do to live 
 Because participants described being informed about OET as a necessary rather 
than possible treatment option, the authors labeled this first stage as being told what I 
need to do to live. All participants described that they first learned of the OET 
prescription early in their treatment of breast cancer. Few participants were surprised 
when informed about needing OET, and most expected it to be part of their treatment. 
Providers told the participants that taking OET markedly decreased their chances of 
recurrence and thus improved their odds of living longer. One 49-year-old American 
woman said,  
“My general surgeon had my test results and showed me that in fact I 
definitely needed to take some sort of an estrogen inhibitor, and there just 
wasn’t any option. I had to take it.”  
Some participants were informed about OET by their surgeon when they were initially 
diagnosed with breast cancer, whereas others were informed later when discussing 
treatment plans with their oncologist.  For example, one 43-year-old woman stated,  
“I was told about it when I first met with my oncologist and she was laying 
out the chemo, kind of the overall plan for me after my surgery.”  
In a few instances, surgeons informed participants about OET, but oncologists 
prescribed it.   
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 Providers emphasized the life-saving potential of OET in a number of different 
ways. Some providers shared detailed facts about OET, and others showed complex 
figures and graphs. Some providers explained risks of recurrence and benefits of OET 
by using a website with information tailored to the participants’ disease. One 42-year-old 
woman explained:  
She [oncologist] plugged in all the numbers based on what I had and 
stage or whatever she plugged in, and there was a 7% chance of it 
coming back if I stayed on the drug for at least five years, at least that's 
what I was told, but if I didn't take the drug, it was a 14.4% chance of it 
returning within ten years.  
 Other participants were simply told that taking OET would definitely reduce the 
chance of recurrence because their cancer was “hormone fed” or “so estrogen” and 
were not provided specific facts and figures. Regardless of how the life-saving potential 
of OET was presented, not taking OET initially seemed unfathomable to the participants. 
One 44-year-old woman stated,  
“It seemed to me - it didn’t seem like a choice to us [she and her 
husband]. If there was a drug that was going to significantly reduce my 
risk of recurrence up to 50%, then it didn’t seem like a choice to us.”   
 While providers explained the benefits of OET, they did not always tell 
participants about potential side effects. Some providers mentioned possible side 
effects, whereas others did not. A 48-year-old woman stated,  
“He [surgeon] gave me a pamphlet. It was about four pages long and he 
said, ‘Here’s your prescription.’ Really no warning from him about side 
effects at all.”   
Several providers stressed that the benefits of OET would outweigh the side effects or 
that the side effects could be addressed if and when they occurred.   
 In some cases, the initial unquestioning acceptance of the need for OET was 
related to the high degree of trust participants had in their providers. When providers 
indicated that OET was necessary, most participants did not question the providers 
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because they were “well educated and highly trained” experts in cancer treatment. In 
addition, some participants simply believed that their provider had their best interests in 
mind. A 46-year-old woman stated,  
“I highly trust my oncologist, and she’s making the best decisions for me, 
so I don’t question her opinion or her directive to take these medicines.”  
 
Doing what I need to do to live  
 Because the participants saw OET as life-saving and accepted their providers’ 
recommendations to take OET without much question, the authors labeled the second 
stage as doing what I needed to do to live. This stage included deciding to take OET, 
getting the prescription filled, and initiating OET. During this stage, the majority of 
participants were ready do whatever they needed to do to have their best chance for 
survival. For example, one 60-year-old woman said,  
“So I went to the pharmacy and I got the exemestane. Looked at the price 
and was horrified and started taking the exemestane.”  
 
Deciding to take OET  
Most participants readily decided to take OET. One 57-year-old woman said, 
“That [tamoxifen] was just the next stage.” Because participants feared a recurrence of 
breast cancer, most were motivated ‘without question’ to take OET, and none seriously 
considered not taking it. One 48-year-old woman said,  
“At that point, there was no question. This is cancer. This is a huge deal. 
If that’s the medicine it takes to deal with it, then that’s what we’re going 
to do.”  
Another 46-year-old woman said,  
“The alternative would be not to do anything or not take it, and the 
alternative didn’t make sense either. Why not do anything when you can 
actually have this medication that helps.”  
These women thus filled their prescriptions soon after receiving them. 
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The few participants who were more hesitant about taking OET delayed getting 
their prescriptions filled until they had more information regarding possible side effects or 
more information on how OET worked. One 53-year-old woman said:  
 “I told her [oncologist] I wanted to research it and see what the side 
effects were and everything and decide. She gave me the prescription, 
then I came home and researched, and I seen (saw) there were a lot 
more side effects than what she had told me. I called the nurse back, and 
all she told me was not everybody has those side effects and I should go 
ahead and try it. I went ahead and tried it.” 
During this delay, these women weighed the benefits and potential risks. One 44-year-
old woman said,  
“I figured that my decision to take it was the risk of it recurring. I would 
rather take the side effects and feel confident that I wouldn’t have a 
recurring cancer.” 
Getting the prescription filled  
Most participants did not feel that getting their prescriptions filled was a significant 
event. The pharmacists told the participants very little about the potential side effects of 
OET, although some provided written information in the form of printouts or pamphlets. 
Some pharmacists gave brief verbal instructions to participants such as “take it on an 
empty stomach” or “try and take it at the same time each day,” but did not provide 
detailed instructions or engage in in-depth discussions about the potential side effects. 
One 43-year-old woman said: 
[Did not receive information] from the pharmacist. They [pharmacist] 
didn’t give me anything. It [information] was just on the bottle to take it. 
There was no pamphlet from the pharmacy. You know sometimes you get 
those things about medication and side effects? There was nothing about 
that one [Tamoxifen]. 
The participants also did not receive information from their pharmacists about potential 
drug interactions. A few participants were concerned about the likely interactions of OET 
with other medications such as insulin or thyroid medication but did not ask their 
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pharmacists. Instead, they sought this information independently. For example, one 56-
year-old woman said: 
When I got my prescription filled, I didn’t read the side effects. I was just 
more concerned about the interaction with my thyroid medication, and I 
found out that there really shouldn’t be any problem that would affect my 
thyroid medication. That was about the limit of what I checked [using 
GoogleTM].  
 A few participants considered the cost of OET when getting their prescription 
filled. However, even when cost was a consideration, participants continued to be willing 
to do whatever it took to get OET. One 52-year-old woman said: 
I have insurance, but for people that don't this is a very expensive drug.  
Even with my insurance, I pay quite a bit for it.  It's $300 a month, and 
that's for the generic.  Luckily I had made my deductible, so I wasn't really 
paying for it at the time. At the beginning of the year it might have been a 
little bit tough coming up with that money. I would have done it if I needed 
to. 
Initiating OET  
Most participants initiated the OET soon after getting their prescriptions filled. 
The fear of cancer recurrence motivated these participants to start their medication right 
away. Participants felt as if starting the medication was “something [they] should do.” A 
51-year-old woman stated, “I took the prescription, I filled it, and I took it.” Another 68-
year-old woman said,  
“I felt like I was aware of the potential [for side effects], but I went ahead 
and decided I was going to give it a try.”   
Most participants immediately initiated the OET because they knew their cancer was 
ER+ and that OET could block estrogen in the body. One 63-year-old woman said,  
“Well, just to know that the cancer was hormone fed and that I needed 
something to stop those hormones. That was the only thing in my head 
that I didn’t think there was any question that I should take it [Tamoxifen].”  
 
Although most participants initiated OET almost immediately after getting the 
prescription filled, some delayed initiating OET. A 46-year-old woman said,  
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“I picked it up, and I didn’t even take it. I had it in my little pantry thing 
where I keep my medicine, and it was another two weeks after that that I 
started taking it.”  
A 60-year-old woman said,  
“I had it [anastrazole] in hand in its little prescription bag for three days 
before I made the decision to start taking the pills.”  
Enduring what I need to do to live 
 Because all participants experienced side effects from OET and tried their best to 
bear them, the authors labeled the third stage as enduring what I need to do to live. The 
participants experienced a wide variety of side effects that varied based on the OET 
type. Some participants experienced side effects immediately, whereas others 
experienced a delay in the onset of the side effects. Most participants attributed the side 
effects to OET, whereas others questioned whether the side effects were due to OET or 
other causes. Most of the side effects were life-altering, and the participants tried a 
variety of management strategies to help with the side effects, sometimes trying various 
things to experience some relief.  
Experiencing the side effects 
All participants experienced side effects that varied by the OET type prescribed. 
Participants who took tamoxifen experienced hot flashes, fatigue, stiffness, constipation, 
alterations in taste and vision, memory loss, sweating, difficulty sleeping, changes in 
mood, changes in appetite, hair loss, vaginal dryness, and diminished sex drive. 
Participants who took AIs experienced hot flashes, headache, joint pain, muscle aches, 
gastro-intestinal upset, vaginal pain, neuropathy, memory loss, difficulty concentrating, 
and difficulty sleeping. Most of the side effects that the participants experienced were life 
altering as they were severe, caused considerable suffering, and interfered with the 
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women’s daily activities. One 63-year-old woman was “surprised by the severity” of her 
side effects. A 40-year-old woman said: 
When I started taking Tamoxifen, I immediately had issues with hot 
flashes that were just crazy hot flashes. I had already had some hot 
flashes because I had started through menopause, but the Tamoxifen hot 
flashes, I went like 36 hours without sleeping because every time I would 
lay my head down I was just like…..it was like my blood was boiling. 
The onset of side effects varied among participants. Some experienced side effects 
almost immediately after initiating OET whereas others experienced them later in their 
treatment.  
Determining the cause of the side effects  
Participants’ recognition of the onset of side effects was affected by variations in 
onset and presentation. Some participants were uncertain whether their side effects 
were directly related to OET or a result of something else such as cancer recurrence, the 
residual effects of cancer, chemotherapy, or radiation. Some participants who had vague 
or ambiguous symptoms, such as difficulty with memory or localized pain in wrists or 
feet, had an especially difficult time determining if their symptoms were due to OET. One 
43-year old woman said,  
“At the beginning, I didn’t know how many of these side effects had to do 
with the end of radiation or the beginning of Tamoxifen.”  
Another 44-year-old woman said, “I didn’t really connect it at that point it was the 
Tamoxifen.” These participants did a number of things to determine whether their side 
effects were OET-induced. Some participants, either independently or in consultation 
with their providers, ceased taking OET for a period-of-time to monitor if side effects 
would stop and then restarted OET to monitor if the side effects returned. One 68-year-
old  woman said: 
I had a lot of GI tract upset. When I went off of it [Aromasin], within three days my 
system was completely totally back to what I would consider normal before this 
happened, so we [oncologist and I] concluded it was the Aromasin. 
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 Other participants looked up information on the internet to see if their side effects 
were common and were experienced by others. One 43-year-old woman said,  
“I guess in some ways it [the Internet] is helpful. I did see that there were 
other people who might be suffering from hair loss from Tamoxifen.”  
Some women got opinions from family and peers about whether the side effects were 
related to OET.  Some family members made the connection between OET and side 
effects for the participants. One 44-year-old woman said: 
That’s when…. I didn’t really connect it [the way I was feeling] at that point it was 
the Tamoxifen. Because it had been so long since I had started taking it, I just 
thought I wasn’t going to have side effects until my husband mentioned it to me. 
It was probably about two months in. He said, ‘maybe that’s what they were 
talking about. Maybe these were the side effects they [oncologist] were talking 
about’. 
Trying to manage the side effects  
The participants tried a variety of strategies to manage their side effects and to 
feel better. Participants who were certain their side effects were from OET found ways to 
treat or manage them almost immediately. For example, one 60-year-old woman said:  
Within three days of that first pill, I took it in the morning and went to bed 
that night three days after I had started it with a vague unusual headache 
because I never have headaches. So then for a week I tried taking 
anastrazole at night figuring well I could sleep with my sleeping pill and 
not be aware of the headache and then tomorrow would be better. 
Others did not engage in management strategies until they were convinced that 
OET was causing the side effects. To manage their side effects, participants 
followed their providers’ recommendations, switched from one OET to another, or 
tried to manage the side effects on their own.  
Following provider recommendations for the side effects  
Many of the participants discussed their side effects with their providers who 
suggested different approaches for management. The providers consulted by the 
participants were those who prescribed the OET, the radiation oncologist or surgeon. 
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Providers prescribed medications such as Lexapro or Neurontin, nutraceuticals such as 
vitamin E or magnesium, behavioral strategies such as exercise or dividing the dose of 
the OET, or integrative therapies such as Reiki. Participants experienced varying 
degrees of relief by following these recommendations. For example, one 44-year old 
woman said,  
“I’m on Lexapro now, and it immediately changed how I’m able to function 
with the side effects from the Tamoxifen.”  
Alternatively, a 54-year-ol woman said,  
“She [oncologist] put me on an antidepressant. It made things worse I 
think. I stopped taking it recently.” 
 Some participants received referrals to providers not directly involved in the 
cancer treatment for management of their side effects. Sometimes the referrals were for 
one-time consultations, such as to a sleep specialist, and sometimes referrals resulted in 
additional referrals. One 67-year-old woman described her experience when she started 
having pain, numbness, and tingling in her wrist:  
I went to my GP [general practitioner], and she thought that I had carpal 
tunnel. She sent me to a neurologist for testing of carpal tunnel. He said, 
‘Yes, you have carpal tunnel.’ I went to an orthopedic doctor. He said, 
‘Yes, you have carpal tunnel, and we can fix it right way.’ He said ‘You 
can have surgery, and you can have it fixed right away.’ I said ‘I don’t 
think I’m bad enough for surgery.’ I saw my oncologist for my regular 
checkup soon after that. She said ‘That is crazy because tendonitis is a 
fairly common side effect of Aromasin, and you would still have tendonitis 
even if they gave you surgery for carpal tunnel.’  
Switching from one OET to another  
Some providers recommended that the participants switch their OET in an 
attempt to alleviate side effects. This recommendation was often in response to severe 
or adverse side effects such as an anaphylactic reaction or a thrombolytic event. In 
some cases, the recommendation followed less severe side effects such as headaches, 
gastrointestinal upset, and diarrhea.  Even though participants switched from Tamoxifen 
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to AIs or from one AI to another, they did not always experience relief. One 70-year-old 
woman said,  
“He [oncologist] said ‘there are some properties in one [aromatase 
inhibitor] that might not be in the other, and it might lessen your joint 
pain.’… I have not found that to be true at all.”  
Some participants, however, did find the switch to be helpful. One 68-year-old woman 
said: 
I started taking it [Letrozole] and didn't experience much for the first few 
weeks, and then I started having the same kind of joint stiffness, hot 
flashes, and a little bit of GI problems, nothing like what I experienced 
with the Aromasin, but a little bit.  By that I mean I might have a couple of 
episodes two or three times a week where it'll just kind of hit me and I'll 
need to be in a bathroom. 
Managing side effects on one’s own  
Many of the participants tried to manage their side effects on their own, prior to or 
without consulting their providers. Some tried nutraceuticals for relief that included 
switching from magnesium citrate prescribed by the oncologist to magnesium glycinate 
for hot flash relief, vitamin B for concentration and memory, vitamin E for hot flash relief, 
increasing vegetable and fiber intake for constipation, and eating bananas and drinking 
coconut water for leg cramps. One provider, however, determined that a participant’s 
nutraceutical strategy for hot flashes was potentially harmful. A 54-year-old woman 
explained: 
I talked to my coworkers, and they said that they took something off the 
shelf from [the pharmacy]. I tried that [supplement], and my oncologist 
told me that was not good because they [supplement] had hormones in 
them. I said I didn’t know that, so I stopped it immediately.  
Some participants tried behavioral strategies and found relief from exercise, yoga, and 
meditation. Others reported relief from using ice packs and wet wipes to cool during hot 
flashes. Other successful strategies including taking OET on a full stomach to avoid 
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nausea, avoiding foods that tasted funny, or writing things down to help with difficulty 
concentrating or remembering. A few participants found relief from Reiki.  
Combining a variety of strategies  
Participants combined the strategies described above in several different ways. 
Very few tried just a single strategy. Several tried strategies sequentially; they tried one 
strategy, waited a while to see if it would work, and then tried another. Others tried one 
strategy after another in a desperate attempt to feel better. Some tried several strategies 
concurrently to see if they could land on something that worked. Some first attempted 
their own strategies and then contacted their providers when their own efforts were 
unsuccessful.  
One 61-year-old woman’s experiences revealed the complexities of managing 
OET side effects:  
The doctor suggested verbally I take some glucosamine and some 
Celebrex. Unbeknownst to me, until I read the label, the glucosamine has 
shell-fish in it, and even though it's a small amount that was what was 
initially making me sick because I'm allergic to shell-fish.  I felt really bad 
….it was totally unbearable. The pain was affecting my sleeping. I was 
provided with some sleeping medication, but it wasn’t really helping. I was 
sent to a sleep specialist who prescribed the generic form of Ambien and 
that helped quite a bit. Oddly, the thing that helped absolutely the most is 
…. Reiki…. when I had the reiki it calmed everything down and made me 
sleep so much better…  As I worked with the sleep doctor getting better 
sleep, I think that also helped with the healing. Then the pain finally just 
started resting in [one area]…I was sent to a doctor who looked at it if 
there was some kind of mechanical problem...  It was that doctor who 
recommended a sugar-free diet, and that helped the inflammation a lot.  
My oncologist in June also recommended an anti-inflammatory diet, but 
this other doctor actually recommended a book that was medical-based 
that had really good information on things that you can do to inflame pain 
in the joints….I also during that time started working out quite a bit, about 
150 minutes of exercise…  
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Deciding how I want to live 
 Because many participants experienced a point-in-time where they decided 
whether the suffering from the side effects was worth the benefits of continuing OET, the 
authors labeled the fourth stage as deciding how I want to live. The participants had to 
decide if they could best live with the side effects or best live without the side effects but 
with the knowledge that their cancer would more likely return. The decision represented 
a pivotal moment for many of the participants. To make this decision, many sought 
additional information or advice from their providers, family, or friends. Some participants 
decided to continue the OET to live as long as possible, some decided to continue the 
OET for now, and some decided to discontinue the OET because they could not, or did 
not wish to, live with the side effects any longer.  
Deciding to continue OET   
Some participants decided to continue OET as long as needed. Most of these 
participants were certain they would continue OET for the recommended time of 5 or 10 
years. One 67-year-old  woman said,  
“My commitment to it [Aromasin] is pretty strong to stick with it for the five 
years…I’ve read how good these work, the Aromasin, the aromatase 
inhibitors, if people stay on them.”  
 
Many participants had talked at length with providers, peers, and family and had 
carefully considered the risks and benefits of OET. The fear of recurrence was 
particularly strong in some of these participants. The support of family, friends, and faith 
helped sustain many of these participants. Some did not want to face the regret of going 
off the OET only to have their cancer return. One 54-year old woman said,  
“Then all I can think is OK, I don’t take this and I was told to and it may 
come back and bite me later I only have myself to blame.”  
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Deciding to continue OET “for now”  
At the time of the interview, some participants were still on OET but were not 
certain they would continue treatment for the recommended time. These participants 
were considering whether the benefit of OET was worth tolerating the side effects. One 
56-year-old woman said: 
“I guess ultimately I need to talk to the doctor and do more research and 
decide what’s going to be better for me. What I’ll feel more comfortable 
doing, stop taking the medicine, praying it [breast cancer] doesn’t come 
back, or just try to manage the symptoms and stick it out for four more 
years….I don’t know if I can go another four years, especially if I’m not 
going to start feeling any better, but then on the other hand I’m kind of 
afraid that if I stop taking it [Tamoxifen] my cancer will come back.” 
 
Deciding to stop OET  
Several participants had decided to stop OET and most of these were confident 
they had made the right decision. Similar to how participants who had made the decision 
to continue OET, participants who decided to stop it thoughtfully contemplated if the 
burden of the side effects outweighed the risk of their cancer recurrence. These women 
sought the advice of providers, families, or friends. One 52-year-old woman said,  
“My next visit I told her [oncologist], and she made it my choice whether I 
wanted to stop…she said if it was causing me problems, it probably would 
be best to go ahead and stop, so that’s what I did.” The one thing that all 
participants who had stopped taking OET had in common was that they 
felt like they could no longer live with the side effects. One 70-year-old 
woman said, “I decided I wasn’t going to live like that the rest of my life.” 
3.5 Discussion 
 The purpose of this study was to develop a theoretical framework that reflects the 
social process through which women’s experiences with OET unfolded over time. Using 
grounded theory methods, we analyzed 31 interviews from women who had experienced 
OET side effects. The framework includes four stages that we labeled being told what to 
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do to live, doing what is needed to live, enduring what is needed to live, and deciding 
how to live. The framework reflects the major finding that women readily agreed to take 
OET when their providers stressed on its life-saving potential but re-evaluated its risks 
and benefits after experiencing life-altering side effects, causing some to terminate the 
therapy. Thus far, most studies measured only the presence, frequency, or severity of 
OET side effects but did not explore women’s personal experiences with these side 
effects. Unlike these studies, our study was an in-depth qualitative inquiry of the 
experiences of women on OET.  
Our study nonetheless confirmed some findings from previous research. Similar 
to our findings that women do not have in-depth discussions with providers and 
pharmacists on the potential side effects before beginning OET, a previous study also 
found that very few patients asked to speak to a pharmacist about their medications. Our 
finding that women often initially struggled to determine if a bothersome side effect was 
in fact caused by OET confirms a finding by Wouters et al. (2013) that providers and 
women often experience uncertainty on whether their symptoms are related to 
menopause, prior chemotherapy, or OET. 3.11 Mao et al. (2013) and Stanton, et al (2014) 
found that when women fail to find relief from side effects after attempting a variety of 
treatment or management strategies, they try switching to a different type of OET 
therapy.3.7,3.10 This finding is consistent with our study. Similarly, our finding that 
switching does not often bring lasting relief was also reported supported by a previous 
study that switching often does not prevent further side effects or decisions to interrupt 
or stop OET.  
The framework we developed should be considered in light of previous theories 
applied to this issue. For example, Goldophin (2009) theorized that shared decision-
making is the crux of patient-centered care and improved the quality of healthcare. The 
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most important attribute of patient-centered care is the active engagement of patients in 
making health care decisions.3.5 Our finding that shared decision-making was often 
absent in early discussions on OET may be likely due to providers being highly invested 
in preventing breast cancer recurrence above all else. This is substantiated by the 
findings of Morrow et al (2011) that the desire to adhere to published treatment 
guidelines inhibited shared decision making. Understanding our findings in the context of 
this theory therefore raises questions about how shared decision-making during the first 
OET prescription can influence women’s experiences managing their side effects if and 
when they occur.  
Another theory that can interpret our framework is the Transactional Model of 
Stress and Coping.3.6 According to this theory, the stress induced by an event or 
situation is mediated by the individual’s appraisal of the stressor. Persons appraise the 
event/situation as well their resources and ability to manage or cope with it. Once coping 
strategies are implemented, they reappraise the stressor. This process can result in 
adaptation to the stressor or changes in their responses, including engaging in specific 
health behaviors.  Among our participants, the initial stressor was the diagnosis of 
ER+BC and the threat of reoccurrence. This threat motivated women to initiate OET 
without much question and initially endure the side effects. Some women found their 
efforts to manage or withstand the side effects to be unsuccessful and reappraised the 
side effects as being unbearable. This reappraisal led to their decision to stop OET or 
have the possibility of stopping OET in the future. The Transactional Model of Stress and 
Coping, therefore, can frame the key dilemma experienced by our participants – the 
tension between the desire to live longer and the desire to live well – as a shifting of 
appraisals. The women continually reappraised the threat of breast cancer reoccurrence, 
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threats posed by OET, and their own coping strategies and resources. The intricacies of 
these reappraisals resulted in their decisions to continue or discontinue OET.  
3.6 Limitations 
Some limitations in this study should be noted. First, the interviews conducted for 
this study required retrospective recall of events, which could cause participants to focus 
only on their most salient experiences, limiting the details they could provide on more 
routine experiences. For example, participants might have focused on the most 
memorable negative aspects of their OET experiences rather than “everyday” 
management strategies. In addition, not having contemporaneous details on the 
women’s thought processes to make on-going decisions about OET, such as a diary, 
limited our evaluation of nuances like making multitude decisions on OET on a daily 
basis. Nonetheless, the women’s narratives provided enough robust data to meet the 
study goals.  
Second, most participants were from a single clinic and thus the nature of their 
healthcare encounters may have been influenced by the culture of that clinic. Most of the 
participants were insured and able to afford their medication. Thus, it is possible that the 
unfolding of their OET experiences could differ in important ways from women who are 
less resourced. The later group’s processes, for example, might be more driven by the 
cost of the medication that lacks in our sample. Last, despite the author’s efforts to 
oversample minority women, there was not enough diversity in the final sample to 
determine if race and/or ethnicity influenced how the participants managed OET 
symptoms. Because non-Hispanic Black women have the highest rate of triple negative 
breast cancer and breast cancer diagnosed at advanced stages, many of these women 
treated in our recruitment sites were not eligible for the study.9 The minority women who 
were included in the sample, however, reported experiences similar to non-Hispanic 
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white women and thus the findings represent experiences that are likely to be common 
to all groups.  
3.7 Implications for Practice  
Despite limitations, the framework contributes to a better understanding of the 
experiences of OET in women diagnosed with ER+BC. Providers can use this 
framework to guide conversations with women who have received an OET prescription 
following a diagnosis of ER+BC. The framework suggests that these women might 
benefit from a clearer understanding of the benefits, risks, and side effects of OET early 
on, more assistance in managing the side effects, and more decision support in the form 
of intentional discussions about decisions to continue OET or to suspend it. Nurse 
Navigators or Clinical Nurse Specialists are well positioned to assist survivors in the 
adjuvant phase of breast cancer treatment in this way, perhaps resulting in an increase 
in the number of survivors who choose to take OET for the recommended duration. The 
findings of this study can alert providers to the difficult and fundamental choice some 
survivors must make between living longer and living well so providers routinely engage 
survivors in meaningful discussions and provide support as they make this life-altering 
decision.  
3.8 Future Research 
Further development of the framework using a longitudinal design with a larger 
and more diverse sample is recommended. A longitudinal study that follows women from 
the time they are prescribed OET until they discontinue it or complete the therapy is also 
needed. Encouraging women to maintain a contemporaneous record of their symptoms, 
their responses to the symptoms, and their on-going decisions about OET will allow a 
more in-depth understanding of the factors that most influence women to discontinue 
OET. Future research studies should also include more racially and demographically 
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diverse participants to allow determination of the influence of racial and socioeconomic 
factors on the experience of OET. Such a sample would reveal whether the experiences 
of low-resourced women differ from women with both financial resources and strong 
social support.  
3.9 Conclusion  
Adverse side effects from OET are a common experience shared by women 
treated for ER+BC. The framework depicts a four stage process that reflects a social 
process through which women’s experiences with OET unfold over time. A key finding 
was that women experience a dilemma between wanting to live longer and wanting to 
live well and they attempt to resolve this by deciding the course of their OET treatment. 
The framework adds to the current knowledge, an in-depth description of the challenges 
that women experience while taking OET and the difficult choices they face. Further 
development of the framework using longitudinal design to obtain narrative data about 
the OET experiences as they unfold over time is recommended. Despite limitations, 
clinicians can use the framework to guide assessment and management of OET side 
effects and to initiate or guide conversations throughout the duration of OET. 
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Chapter 4 
This chapter presents a typology of the decisional needs and supports in women 
with ER+breast cancer experiencing OET side effects.   
4.1 Background 
Millions of women worldwide take oral endocrine therapy (OET) as standard 
therapy for estrogen receptor-positive breast cancer (ER+BC).4.1 OET is prescribed for 
breast cancer survivors (BCS) to prevent reoccurrence by blocking certain hormones 
that fuel cancer growth. OET side effects are common and vary by type of OET 
prescribed. Tamoxifen side effects may include hot flashes, weight gain, loss of libido, 
and/or thromboembolic disease or endometrial pathologies.4.2 Aromatase inhibitor (AI) 
side effects may include hot flashes, arthralgias, fractures, rashes, and/or 
gastrointestinal upset.4.2 Women who report experiencing OET side effects are two to 
four times more likely to discontinue OET earlier than the recommended five year period 
than women who do not report side effects.4.3-4.7 To date, most studies have measured 
the presence, frequency, or severity of OET side effects but have not explored women’s 
personal experiences with these side effects, including their decisions to continue or 
discontinue the therapy as a result.4.10 A better understanding of how women make such 
decisions is needed.  
The Ottowa Decision Support Framework (ODSF) is an evidence-based, 
practical, mid-range theory for guiding patients in making such important health-related 
decisions.4.8 The framework considers all persons (e.g., individual, family, couple, 
provider) involved in the decision-making. According to the framework, quality decisions 
occur when persons’ decisional needs are met and appropriate decisional supports are 
provided.4.8 Decisional needs are what persons require to make quality decisions, such 
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as an understanding of all options; information about the side effects, risks, and benefits 
of each option; clarification of values and priorities; and an awareness of available 
resources. Decisional supports include sources of help available to persons faced with 
making health-related decisions. Supports can provide facts or probabilities, help clarify 
persons’ values and needs, and facilitate their progress.4.8 External decisional supports 
are resources in the person’s environment that provide help with decision making. Such 
supports can include clinical counseling, decision aids, and coaching. The quality of 
persons’ health-related decisions affects their actions or behavior, their health outcomes, 
and their use of health services. 
Designing strategies to support ER+BCS in continuing OET for the 
recommended length of time requires information about their decisional needs and 
supports regarding continuing or discontinuing the therapy. Such strategies could help 
women identify, enlist and/or leverage sources of external decisional support to improve 
the quality of their decision-making. The purpose of this qualitative study was therefore 
to describe decisional needs and external decisional supports among ER+BCS who 
reported experiencing side effects due to OET.  
4.2 Methods  
Basic qualitative description methods as described by Sandelowski (2000) 
guided the study.4.9 This method was selected because it allowed for a straightforward 
description of a phenomenon of interest.4.9Qualitative description uses low-inference 
analysis to provide a comprehensive summary of a narrative data set in everyday 
language. Because the study purpose was to provide a comprehensive description of 
the types of common decisional needs and external decisional supports in ER+BCS, 
rather than a highly interpretive or theoretical rendering of data, qualitative description 
was the most applicable method to meet the study aims.  
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Following both Institutional and Scientific Review Board approvals, the research 
team recruited women through community and provider-supported methods. Some 
methods used for recruitment included strategically placing study fliers in areas where 
women who were diagnosed with cancer were likely to frequent (e.g., clinic waiting 
rooms), creating a Facebook study page and sharing the page with BCS groups, using 
Facebook paid advertising, and sending study information via mail to potentially eligible 
women identified through clinic- and registry-based databases.  
Potential participants were invited to call a phone number or email study staff if 
they were interested in participating and were screened for eligibility by the first author. 
Women were eligible for participation if they were between the ages 40 and 75 years, 
had a first time diagnosis of ER+BC, had completed primary therapy, had initiated OET 
6-24 months prior, and were able to read, speak, and understand English. Women were 
not eligible for participation if they had a health proxy or guardian that made decisions on 
their behalf, reported a diagnosis of a current or previous serious mental disorder such 
as psychosis or dementia, or were unable to recall their OET decision-making over time.  
An interview was scheduled with eligible participants. Before the interviews 
started, participants provided consent to participate. They also provided demographic 
information and information about their BC treatment history. A semi-structured interview 
guide was developed. The guide asked participants to describe decisions they had made 
about their OET, what needs they had to make these decisions, and what supports they 
had received or desired in making the decisions. All interviews were tape recorded and 
transcribed verbatim for analysis. Participants received a $35.00 gift card in recognition 
of their time and effort.  
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4.3 Analysis 
The research team analyzed interview narratives with standard content analytic 
procedures. The research team included four doctoral-prepared nurse scientists and a 
psychologist. Three team members read all transcribed interviews in their entirety. The 
first author (PhD candidate) highlighted all text units (words, phrases, sentences) that 
were related to OET decisions, decisional needs, and external decisional supports 
discussed by the participants. These text units were coded with a label that captured the 
essential meaning of the text unit. Using a series of data display tables to group similar 
codes together, three team members divided the codes into categories. The categories 
were then organized in a two-by-two table to display the categories reflecting the 
decisional needs revealed by the participants and categories reflecting the kinds of 
external supports they believed that could met those needs. The entire team reached 
consensus on the categories through discussion occurring at regular team meetings, 
frequent reexamination of the data, and review of findings. The final analytic product was 
a typology reflecting four kinds of decisional needs and six types of external supports.  
4.4 Results 
Sample  
The final sample included 31 ER+BCS, 58% of the initial pool of interested 
women (Figure 4.1). The type of OET prescribed for the women varied, and the sample 
included those who continued OET, switched to a new type of OET, or discontinued 
OET (Figure 4.1). Demographic characteristics are shown in Table 4.1. The mean age of 
the participants was 55.39 years old (SD = 8.57, range 42-70 years).  
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Typology 
All participants discussed a variety of decisions about OET, including whether to 
begin the therapy, how to manage the side effects, and whether to continue the therapy 
as prescribed.4.10 They identified four needs they had while making these decisions: (1) 
information about OET and its side effects, (2) in-depth discussions about side effects, 
(3) help in managing side effects, and (4) emotional support. The participants also 
identified six sources of external decisional supports who/that helped them meet these 
needs: (1) healthcare providers, (2) husbands, (3) other BCS, (4) friends and family, (5) 
the internet and other media sources, and (6) God. The resulting typology is shown in 
Table 4.2. Below, we describe how each source of external decisional support met, or in 
some cases failed to meet, one or more of the participants’ four decisional needs. 
Healthcare Providers  
Many participants identified healthcare providers as sources of support for their 
decision-making about OET. Providers included nurses, physicians (e.g., surgeons, 
radiation oncologists, medical oncologists), pharmacists, and social workers. Healthcare 
providers were involved in meeting all decisional needs. 
Information about OET and its side effects. Participants often looked to 
healthcare providers for information about OET and its side effects in order to make 
decisions about their therapy. Most providers routinely gave this information in 
pamphlets or printouts that included descriptions about the types of OET and the 
possible side effects of each type. The participants generally found such information 
helpful. For example, one 53-year-old participant said,  
“It [printed information] was helpful…. It was nice because it was in 
written form, and that way because sometimes when you’re in the office 
it’s overwhelming, and then you can go home and look at it at your 
leisure.…”  
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Some participants, however, found the information they received to be 
inadequate, and some women did not receive any printed information at all. These 
participants suggested that a printout or pamphlet that described the benefits and risks 
of OET would have been useful. For example, one 51-year-old participant said,  
“It would be kind of helpful to have something that you could read about 
the pros and cons of some of the different choices maybe just to have as 
a reference… and even to have a doctor give it to you.” 
In-depth discussions about OET side effects. Some providers did not simply 
provide information but rather engaged in in-depth discussions with participants about 
the side effects of OET, and this aided women’s decision-making. Several providers, for 
example, talked at length with participants about the different types of side effects that 
could occur with different types of OET. One 52-year-old participant said,  
“She [the oncologist] pretty much told me what I could expect or if I had 
these side effects that's one of the things that the drug could cause.”  
Another 44-year-old participant said,  
“She [the oncologist] really did inform me well about what side effects she 
had witnessed personally in her practice.”  
Other providers initiated in-depth discussions on how OET works generally in preventing 
reoccurrence. These discussions helped participants decide to continue with OET 
despite its side effects by increasing their awareness of the life-saving potential of the 
therapy.  
Other providers did not have in-depth discussions about side effects and this left 
the participants feeling uncertainty about whether the side effects they experienced were 
from the OET, another cancer, breast cancer treatment, or aging. One 56-year-old 
participant said,  
“Since I've been taking this for a while now and the last visit that I had, I 
am kind of questioning whether some of the things that I'm experiencing 
is because of the medication.”  
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Also, in the absence of these discussions some participants questioned whether or not 
they could endure the OET for the duration of time it was prescribed. One 56-year-old 
participant stated,  
“I feel like I can’t make a very good decision one way or the other if I want 
to continue this. I guess the only way to find out if it’s the medication 
[making me feel this way] is to stop taking the medication [OET] and see 
if I feel better.” 
Help managing side effects. Some participants looked to their providers not just 
for discussions about their side effects but for help in managing them. Several providers 
prescribed medications such as clonidine or Effexor for hot flashes. Others 
recommended supplements such vitamin E or magnesium or behavioral strategies such 
as using a fan while sleeping or a cooling gel pillow for hot flashes. One 49-year-old 
said,  
“That was when she [oncologist] said we can do something about that, 
and so she prescribed the clonidine.”  
Another 53-year-old said,  
“The oncologist told me we're going to block your estrogen. There's a 
chance that you'll get hot flashes. A lot of people experience hot flashes 
taking the medication. If they get horrible, we'll try some things.”  
Some providers offered a variety of approaches for managing the side effects. A 58-
year-old participant said: 
“I saw her [oncologist] a month later, and she asked me how I was doing 
on it [Tamoxifen], and I told her it was terrible. I hated it. It gave me night 
sweats. I didn't sleep well. It was not a good thing. I felt like I was 
complaining. She said you don't have to suffer. Let's just split the pill into 
two.”  
Receiving such helped support the participants’ decisions to continue their OET by 
providing hope that there were ways the side effects could be eliminated, lessened, or 
tolerated.  
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 Not all participants, however, received help from their providers in managing 
their side effects. One 60-year-old participant said,  
“I called her [oncologist] for something because I knew I was battling this 
anxiety. I don’t remember what the question was. I called and left a 
message on her voice machine and she never called me back.” She said, 
“I wish there had been an agreed-upon symptom management plan 
spelled out or handed to me on a sheet.”  
Emotional support. The participants also welcomed emotional support from their 
providers and found that this aided their decision to continue their OET despite  side 
effects. These providers listened to the participants, were accessible outside of patient 
visits, and were attentive to their concerns. For example, one 61-year-old participant 
described her providers as  
“encouraging people who really listen to your concerns and take them 
seriously, understanding that my body is different than other peoples and 
treat me like a person, a whole person.” 
Another 68-year-old participant said,  
“There's always been follow through. When I've been told I'll get a phone 
call back, I'll get a phone call back. Questions have been answered.”  
Some participants, however, did not receive emotional support from their 
providers, especially when they voiced concerns about their side effects. For example, 
one 53-year-old participant said,  
“I just feel like she [Oncologist] didn’t really listen to me, take time to really 
listen to me about my side effects, so I decided to look for another 
oncologist.” Another 46-year-old participant said, “I felt like the support 
wasn't really there that I needed.” 
Husbands 
Many participants identified their husbands as important sources of support for 
their decision-making related to OET. We suspect other types of stable partners would 
also offer support in similar ways but the participants in our study only mentioned their 
husbands. The participants discussed some ways in which all four decisional needs 
could be met by their husbands.  
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Information about OET and its side effects. Several husbands provided support 
by encouraging participants to seek additional information about OET and its side 
effects. For example, one 44-year old participant said, “My husband – it’s all about ‘Let’s 
get the information. Let’s get all the details.’” Other husbands helped participants 
understand information given by providers. A 51-year old participant said,  
“Sometimes it was difficult to read through those studies because they 
were pretty technical, medical jargon, but my husband helped me 
understand those.” 
In-depth discussions about side effects. Several participants relied on 
discussions with their husbands to make decisions about their OET. Some couples 
discussed whether or not the participants should switch to a different OET because of 
side effects. For example, one 59-year old participant said  
“When making the decision to switch….My husband was there too, and 
we were like yeah, we feel more comfortable doing that so that’s why we 
switched to the Arimidex.”   
Another 53-year old participant had discussions with her husband about her side effects 
that encouraged her to continue with the OET:  
“My husband said, ‘Give it some time. It’ll level off. Just give it some time. 
Your body has been through a lot. It’s all new.’” 
Help managing side effects. The husbands provided help in managing the 
participants’ side effects in several ways. Some husbands recalled details of side effect 
management strategies given by the provider during visits that participants might have 
forgotten. Others recognized the participants’ side effects before they did and 
encouraged them to report these side effects to their providers. For example, one 58-
year old participant said,  
“When I talked to her [oncologist] the next month, I was kind of reluctant 
because I thought I was being a big baby to talk to her about it, but my 
husband was right there with me. He encouraged me to say I just really 
don’t like the way it makes me feel at all.” 
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Some husbands helped manage the participants’ side effects in practical ways. A 60-
year old participant revealed,  
“During bad bouts of lupus flair [from OET] my husband was hoisting me 
out of a chair and helping me out of the bathtub. Raising my legs in the 
bed at night. And asking me ‘What do you need me to do for you?’”  
Emotional support. One major way that husbands provided support to the 
participants as they made decisions about OET was by “being there” for them. Many 
husbands accompanied their wives to their doctors’ appointments, and the participants 
felt encouraged by this. Husbands provided emotional support by reminding participants 
to take their OET. A 48-year old participant said, “Then my husband was asking me did 
you take the [OET] prescription?” Husbands were also supportive by being generally 
caring and attentive. One 44-year old said, “My husband is a very strong support to me.”  
Other BCS 
The participants also identified other BCS as sources of support for decision-
making on OET. The other survivors could be friends, coworkers, or strangers 
encountered through social media. The participants indicated that all four decisional 
needs could be met in some fashion by other BCS. Participants who were unable to 
share their OET experience with another survivor indicated that it may have been helpful 
to talk with someone who had experienced what they were going through. 
Information about OET and its side effects. Participants found that information 
from other survivors available on the internet to be helpful as it provided some insight 
into whether or not the side effects experienced by the participants were related to OET. 
For example, one 59-year old participant said,  
“I looked up a lot of blogs on the internet to see if other people were 
experiencing those, if they had those symptoms. Some people seem to 
have those symptoms.” 
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In-depth discussions about side effects. Participants and other breast cancer 
survivors discussed their OET experiences, commiserated over their side effects, and 
shared how they made decisions about continuing or discontinuing the treatment. For 
example, one 49-year old participant said,  
“They [friends with breast cancer] would listen to me. They would give me 
their story. They would tell me how they came to their decisions [about 
OET].”  
Another 57-year old shared,  
“There was a lady I remember from the breast center I met when getting 
radiation who said, ‘I‘ve taken this [OET] for six years and it doesn’t 
bother me. I have zero side effects. It’s fine. You’ll be fine’.” 
Help managing side effects. Other survivors also provided support by sharing 
specific strategies they had used to manage their side effects. The participants found it 
helpful to speak with others who knew what might really work. For example, one 57-year 
old participant shared,  
“Because I had people that had gone through this that I talked to, at least 
three or four women, seriously talked to about what can ease all of these 
side effects. I took what they said and did it.”  
Another 68-year old participant shared: 
“Just talking with someone who was coming from a little bit less of a 
medical perspective and her explaining to me some of the things that she 
had tried as far as helping with the hot flashes and helping with the 
energy and those kinds of things was really helpful.” 
Emotional support. Other survivors provided emotional support by encouraging 
the participants to endure the side effects of OET because it was so important in 
preventing reoccurrence. These survivors gave reassurance that taking OET would be 
worth it and provided hope for the participants. For example, one 48-year old participant 
shared,  
“I go to a support group periodically, and the ladies there have been very 
supportive of you need to do this [tamoxifen]. You don’t need to give up. 
You don’t need to quit when it’s so important.”  
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Another 49-year old shared a conversation with her coworker who had been diagnosed 
with cancer:  
“She [coworker also diagnosed with cancer] just wanted somebody [me] 
to tell her it was okay to feel whatever she was feeling. I had had all of 
these other women who had done that for me and their willingness to talk 
about their experience, to talk about their feelings, to be vulnerable again, 
but to be vulnerable again so it would help somebody, which was me.” 
Friends and Family 
Some participants identified friends and family as sources of support for decision-
making related to OET. These persons could be anyone who was close to and cared 
about the participant’s well-being. The participants discussed ways in which the external 
decisional need of emotional support could be meet by friends and family.  
Emotional support. Friends and family provided emotional support by being 
available to participants in times of need. One 50-year old shared,  
“And I have a good friend that I tell her… She is not a cancer survivor or 
anything but I’ll be like everybody thinks I am just fine and I am just not.”  
In addition, family and friends gave referrals for providers. For example, one participant 
53-year old participant shared, “He’s [coworker] the one who helped me find my 
oncologist.”  
Not all friends and family, however, provided support. One 53-year-old participant 
revealed, 
“I would say I’m having really bad side effects from this, and then she 
[daughter] would say, ‘Well, at least you didn’t go through chemo, Mom. 
Just keep thinking that you’ve only got to take this for three more years or 
whatever.’ She would always say that. That’s why I just try to push 
through hoping it will get better.” 
The Internet and Other Media Sources 
Several participants indicated that the internet and other media sources such as 
books, research articles, and printed reports served as a source of support for decision-
making related to OET. The participants discussed ways in which two decisional needs 
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could be meet by these sources: information about OET and its side effects, and help in 
managing side effects.  
 Information about OET and its side effects. Participants often obtained general 
information about OET and its side effects from the internet by “Googling” their 
questions. For example, one 50-year old said,  
“I had read [on the internet] something that was one of the most effective 
parts of the whole treatment was taking something like that [OET], 
especially if you were estrogen receptor positive….”  
Participants obtained information on what types of OET were available, why different 
types of OET are prescribed, and how OET works to decrease the risk of breast cancer 
reoccurrence from the internet and other informational sources. For example, one 53-
year old said, “For me, seeing the research knowing that this was the best option was 
helpful.” One 63-year old participant revealed how much a particular book had helped 
her because it had so much information in it.  
Management of side effects. Participants also obtained information about 
managing side effects from the internet and other informational sources. For some 
participants, this information was particularly helpful because it came from a source that 
they deemed credible. Some strategies obtained from the internet included how to 
manage nausea, hot flashes, and interruptions in sleep. One 48-year old shared,  
“I talked to Dr. Google about it some and found out there’s things with 
Tamoxifen that you can take it at night, and I had been taking it in the 
morning.” 
God  
A few participants indicated that God served as a source of support for decision-
making related to OET. These participants discussed ways by which their faith provided 
emotional support while they made decisions about their OET. 
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Emotional support. Some participants found solace in the belief that God would 
assure that they made the right decisions about their OET. One 60-year old shared,  
“And underlying everything is my strong Christian faith and belief in a God 
whose plan for me is never wrong.”  
Another 46-year old participant said,  
“I believe in God, and I believe there’s a higher power. I know ultimately 
he has all the answers.” 
4.5 Discussion 
Because OET might be prescribed for as long as a 10 year period, and is 
accompanied by a myriad of troublesome side effects, women need to make many 
decisions about their therapy over a long period of time. Due to the life-saving nature of 
the therapy, the most critical decision is whether or not to continue the therapy.4.11Our 
study revealed that women who take OET had several decisional needs and found 
external decisional supports from a number of different sources. Their needs ranged 
from practical information about side effects and how to manage them to the emotional 
support of providers and close family and friends who listened to them and expressed 
their understanding of what they were experiencing.  
Decisional needs  
Our findings regarding the types of decisional needs identified by ER+BCS 
resonated with several prior studies. For example, a study by Kahn et al. revealed that 
OET communication that included discussion of OET side effects was a positive 
predictor of patient adherence.4.7 This finding was supported by the narratives of our 
participants who claimed that having clear information about side effects and how to 
manage them helped them continue on OET despite the aversive and life altering side 
effects. Our findings about instances when ER+BCS did not have their decision needs 
meet by their providers are similar to the findings by Kimmick et al. (2015).4.12  These 
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researchers reported that women’s difficult-to-manage OET side effects are rarely 
adequately addressed by providers even with regular follow-up after breast cancer 
treatment.4.12 Our findings extend the knowledge on what is known about the decisional 
needs of ER+BCS by revealing that these needs often extend beyond the need for 
information and management strategies and at times include the need for in-depth 
discussions about the side effects and the support of others who appreciate the extent of 
their suffering due to the side effects they experience.  
External decisional supports 
Our finding on the external decisional supports of ER+BCS also is consistent with 
prior research. Our finding, for example, that the internet is an important external support 
was also reported by Fogel et al. (2002). These researchers found that many cancer 
patients use the internet to make informed choices often because they find it more 
comfortable to seek information over the internet rather than use traditional cancer 
support services.4.14 
  However, our findings on the role of family and friends as external supports 
differed from the findings of Van London (2014).4.13In that study, women described 
receiving little understanding and support about symptoms from family and friends and 
felt husbands only wanted to hear about OET experiences for a limited amount of 
time,4.13 whereas our results revealed that husbands and family and friends were strong 
sources of decisional support. Our findings extend the work of previous researchers by 
delineating multiple sources of external support and demonstrating how different sources 
of support meet, or fail to meet, a variety of needs in different ways.  
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4.6 Limitations 
Limitations of this research should be considered. First, the majority of 
participants were highly resourced with income, insurance status, and social support. 
This may have resulted in an identification of needs and supports that were more similar 
than dissimilar. For example, the decisional needs of our sample were typically met by 
one of the sources they identified, whereas a lower resourced sample might have 
provided a more robust discussion of unmet needs. All patients in this study came from 
one clinic, which might have limited our findings especially to variations in the decisional 
supports received from healthcare providers. Women not treated in an academic health 
center, for example, may experience different types of provider supports. Because our 
sample was fairly homogeneous in terms of race, we were not able to compare needs 
and supports across racial groups. In addition, our interviews did not include specific 
structured questions about how each decisional need was met or unmet by each source 
and therefore some sources may have provided supports that were not captured in the 
interviews.  
4.7 Implications for practice 
Our study highlights the important role of healthcare providers in providing 
external decisional support for ER+BCS. Our findings suggest that providers need to be 
mindful that information alone may not be enough for some ER+BCS, and many may 
need significant and on-going support from providers if the women are to continue OET 
for the recommended duration. Providers need to not only provide information about the 
potential side effects of OET but to thoroughly and thoughtfully discuss them with 
ER+BCS.  Some women will likely only continue OET if their provider is actively involved 
in helping them understand, manage, and eliminate or tolerate the side effects for the 
recommended duration. Providers need to convey to women that they understand that 
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the experience of the side effects can be life-altering and that they appreciate that the 
management of the side effects can be an on-going and arduous process. 
Our finding that women use a variety of external supports when making decisions 
about OET might prompt providers to inquire about the sources of external support 
available to each woman in order to guide referrals. For example, providers might 
recommend a local support group if a woman desires to receive or give support to other 
survivors. Similarly, providers might recommend legitimate internet sources or help 
women determine which sources are reliable. Providers might also inquire whether 
women have the support they need from important others in their lives to withstand the 
side effects. 
This typology thus can be used as a springboard to prompt conversations about 
OET decisions and to assess the needs and supports women have or may desire to 
have while make decisions about OET, especially whether to continue or discontinue the 
therapy.  Findings can also provide foundational informational to develop decision aids 
that address decisional needs and provide new or capitalize on existing sources of 
external decisional supports.  
4.8 Conclusion  
The decisional needs and supports of ER+BCS who experience OET side effects 
and who are thus faced with making decisions about whether or not to continue OET are 
varied. The findings of this study can alert providers to the decisional needs of this group 
of women. In addition, findings can help providers ascertain the best ways they might 
provide decisional supports to enable women to continue the therapy for the 
recommended period of time and thus experience its potentially life-saving benefits.  
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Figure 4.1. Participant Accrual and Prescribed Oral Endocrine Therapy 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
Figure 4.1. Study accrual of participants from screening through analysis including 
reasons for exclusion and type of oral endocrine therapy (OET). N=number of 
participants. Of the 31 participants included in the analysis, 8 were taking their initially 
recommended Aromatase Inhibitor (AI) prescription, 12 were taking their initially 
recommended Tamoxifen (TAM) prescription, 2 participants had switched from TAM to 
AI (TAM:AI), 1 participant had switched from AI to TAM (AI:TAM), 3 had switched from 
one AI to another AI (AI:AI), 4 participants had stopped OET, and one participant had 
stopped OET after switching from one AI to another AI (AI:AI:discontinue). 
  
Assessed for eligibility 
(n=51) 
Excluded –  
  Ineligible (n=17) 
 Second diagnosis of breast cancer 
(n=3) 
 Not ER+  (n=1) 
 OET prescription > 24 months ago 
(n=4) 
 No OET side effects (n=5) 
 Did not initiate OET (n=3) 
 Still receiving primary therapy (n=1) 
 
Included in Analysis (n=31) 
 AI (n=8) 
 TAM (n=12) 
 TAM:AI (n=2) 
 AI:TAM (n=1) 
 AI:AI (n=3) 
 Discontinue (n=4) 
 AI:AI:discontinue (n=1) 
 
Found ineligible during interview (n=3) 
Enrolled (n=34) 
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Table 4.1: Sociodemographic and Breast Cancer Treatment Characteristics of the 
31 Participants 
Race/Ethnicity N (%) 
  White, non Hispanic or Latino 26 (90.3%) 
 White, Hispanic or Latino 2 (6.5%) 
 African American, non Hispanic or Latino       
More than one race, non Hispanic or Latino     
  2 (6.5%) 
  1 (3.2%)   
Marital status 
  Single 2 (6.5%) 
  Married 28 (90.3%) 
  Widowed 1(3.2%) 
Employment status 
  Employed full-time 17 (54.8%) 
  Employed part-time 5 (16.1%) 
  Homemaker 4 (12.9%) 
  Retired 5 (16.1%) 
  Other (self-employed) 1 (3.2%) 
Income (able to pay for things like housing and food) 
  Difficulty  2 (6.5%) 
  No difficulty  29 (93.5%) 
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Table 4.2. Typology of Decisional Needs. 
Decisional Needs 
 Information 
about OET 
and its side 
effects 
In-depth 
discussions 
about side 
effects 
Help 
managing 
side effects 
Emotional 
Support 
 
 
External 
Decisional 
Supports 
Healthcare 
providers 
X X X X 
Husbands X X X X 
Other breast 
cancer survivors 
 X X X 
Friends and 
Family 
   X 
Internet/other 
media sources 
X  X  
God    X 
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Chapter 5 
5.1 Summary of Dissertation Project 
Oral endocrine therapy (OET) is standard therapy for millions of estrogen 
receptor-positive breast cancer survivors (ER+BCS). OET significantly reduces BC 
recurrence, mortality, and metastasis. ER+BCS often do not take their OET as 
recommended due to adverse side effects.  
The purpose of this dissertation was to develop an explanatory framework of 
decision making by women with ER+BC who reported experiencing side effects from 
OET. This project comprised two components and resulted in three manuscripts.  
The first component  was a systematic review with three main findings: (1) Side 
effects negatively impact OET non-adherence; (2) absence of decisional supports 
provided to or available for ER+BCS who are experiencing OET side effects was 
observed; and (3) ER+BCS likely have unmet decisional needs on OET. This manuscript 
is presented in Chapter 2 and was accepted for publication in Cancer Nursing.1 
The second component was a grounded theory study of 31 ER+BCS who 
reported OET side effects. During a single semi-structured interview, participants 
described their experiences with OET over time. Specific aims of the grounded theory 
study were the following: 
Aim 1: Describe responses to OET side effects among women with ER+ BC.  
Aim 2: Identify common decisional needs of women with ER+ BC who report 
experiencing OET side effects. 
Aim 3: Identify common decisional supports sought by and provided to women with ER+ 
BC who report experiencing OET side effects.  
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Aim 4: Describe how women with ER+BCS who report experiencing OET side effects 
make decisions about initiating, continuing, switching, and/or discontinuing OET.  
 This study produced two qualitatively derived products. The first product was a 
theoretical framework that depicted four stages through which the experience of OET 
decision making unfolded. The stages were (1) being told what I need to do to live, (2) 
doing what I need to do to live, (3) enduring what I need to do to live, and (4) deciding 
how I want to live. This framework is presented in Chapter 3.  
The second qualitatively derived product was a typology that depicted six 
sources of external decisional supports (healthcare providers, husbands, other breast 
cancer survivors, friends and family, the internet and other media sources, and God) that 
met four types of decisional needs (information about OET and its side effects, in-depth 
discussions about side effects, help in managing side effects, and emotional support). 
This typology is presented in Chapter 4.  
5.2 Synthesis of Key Findings 
The first key finding was the need for nurses to conduct more research into the 
decision making process of ER+BCS who reported experiencing OET side effects. The 
main findings of the review paper were: (1) OET side effects can lead to ER+BCS 
stopping OET before the recommended duration, and (2) ER+BCS have decisional 
needs related to OET. The review published in Cancer Nursing (Chapter 2) identified 
gaps in knowledge that provided the impetus to conduct the dissertation research. This 
review showed that most existing studies measured only the presence, frequency, or 
severity of OET side effects but did not explore women’s personal experiences of these 
side effects, and that there was no existing in-depth qualitative inquiry of the experiences 
of women on OET. 
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The second key finding was the grounded theory framework. The framework 
emerged from grounded theory analysis of data collected for Aims 1 and 4 (see pages 6, 
7 or 95, 69).The framework reflects a social process through which women’s 
experiences with OET unfolded over time. Commonalities in the participants’ narratives 
suggest that this process included four stages. Because the four-stage framework is a 
conceptual rendering of a common process, it does not necessarily capture the full 
heterogeneity of the participants’ experiences. For example, while many of the 
participants experienced these stages chronologically as described below, not all 
participants experienced each stage, and some experienced the stages in a different 
sequence or for differing lengths of time. The framework nonetheless represents a 
typical trajectory for women who are prescribed OET and who experience side effects. 
The framework reflects the major finding that women readily agreed to take OET when 
their providers stressed its life-saving potential but re-evaluated its risks and benefits 
after experiencing life-altering side effects, causing some to terminate the therapy. 
The third key dissertation finding was the typology of needs and supports. The 
typology emerged from content analysis of data collected for Aims 2 and 3 (see pages 
6,7  or 95). The typology was organized according to the source of potential external 
decisional support by decisional needs. Six sources of external decisional support and 
four decisional needs were identified. Because OET might be prescribed for as long as a 
10 year period, and is accompanied by a myriad of troublesome side effects, women 
need to make many decisions about their therapy over a long period of time. Due to the 
life-saving nature of the therapy, the most critical decision is whether or not to continue 
the therapy. The findings of this study revealed that women who take OET have several 
decisional needs and found external decisional support from a number of different 
sources. Their needs ranged from practical information about side effects and how to 
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manage them to the emotional support of providers and close family and friends who 
understood what they were experiencing.  
5.3 Strengths of Dissertation 
A strength of this dissertation is its ability to address existing gaps in previous 
research by providing an in depth description of women’s OET decision making 
experiences. To my knowledge, this is the first study to generate an explanatory 
framework for decision making by women with ER+BC who reported experiencing side 
effects. Although we have known that side effects contribute to women's decisions to 
stop OET, this study has clearly described women receiving insufficient information 
about side effects from providers, and their desire to seek additional information. This is 
the first study to clearly unravel the details of the decision making process of OET 
adherence by ER+BCS. Thus, the dissertation findings contribute new information to 
nursing, medicine, oncology, and symptom science by expanding the understanding of 
how OET side effects contribute to non-adherence and poor patient outcomes. Findings 
from this in-depth qualitative study can be used to develop interventions, such as 
decision aids, to promote quality decision making and improve the quality of health 
outcomes of breast cancer survivors taking OET. 
5.4 Limitations of Dissertation 
Our findings should be understood in the context of several study limitations. 
First, the interviews conducted for this study required retrospective recall of events and 
this could cause participants to focus only their most salient experiences and limit the 
amount of details they could provide about their more routine experiences. For example, 
participants might have focused on the most memorable negative aspects of their OET 
experiences rather than on the “everyday” ways they tried to manage the side effects. 
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Not having contemporaneous details about the thought processes the women used to 
make on-going decisions about OET, such as those that may be available in a diary, 
limited us in explicating the nuanced processes likely to be involved in the multitude of 
decisions the women needed to make about OET on a daily basis. Nonetheless, the 
women’s narrative accounts provided enough robust data to meet the study goals.  
Second, most participants were from a single clinic and thus the nature of their 
healthcare encounters may have been influenced by the culture of that clinic. As a result, 
most of the participants were insured and able to afford their medication and it is 
possible that the unfolding of their OET experiences could differ in important ways from 
women with fewer resources. The latter group’s processes, for example, might be more 
driven by the cost of the medication and lack of support in comparison with our sample. 
In addition, this may have resulted in an identification of needs and supports that were 
more similar than dissimilar. For example, the decisional needs of our sample were 
typically met by one of the sources they identified; whereas a lower resourced sample 
might provide a more robust discussion of unmet needs. 
Third, despite the team’s effort to oversample minority women, including 
contacting all minority women within the available population, there was not enough 
diversity in the final sample to determine if race and/or ethnicity influenced how the 
participants managed OET symptoms. Because non-Hispanic Black women have the 
highest rate of triple negative breast cancer and breast cancer diagnosed at advanced 
stages, many of these women treated in our recruitment sites were not eligible for study. 
The minority women who were included in the sample, however, reported very similar 
experiences to Caucasian women and thus the findings represent experiences that are 
likely to be common to all groups.  
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5.5 Summary of Recommendations for Future Research 
Further development of the framework presented in this dissertation using a 
longitudinal design with a larger and more diverse sample is recommended. A 
longitudinal study that follows women from the time they are prescribed OET until they 
discontinue it or complete the therapy is also needed. Encouraging women to maintain a 
contemporaneous record of their symptoms, their responses to the symptoms, and their 
on-going decisions about OET will allow a more in-depth understanding of the factors 
that may most influence women to discontinue OET. Future research studies should also 
include more racially and demographically diverse participants to allow determination of 
the influence of culture and socioeconomic factors on the experience of OET. Such a 
sample would reveal whether the experiences of low-resourced women differ from 
women with both financial resources and strong social support.  
Additional recommendations for future research are to use these innovative 
findings for future intervention research. The narrative accounts provided during the 
interviews provide descriptive information that can be used to generate interventions to 
improve quality decision making. For example, findings about decisional needs and 
supports can be used to develop a decision aid. Next steps in this research would be to 
use the identified information decisional needs and their requirements for decisional 
supports to develop a draft of a decision aid. Then, after review of the decision aid by 
stakeholders of patient and provider groups, revisions would be made from 
recommendations prior to conducting field tests with patients. Findings of field testing 
would then be peer reviewed or appraised by individuals not involved in its development.  
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5.6 Summary of Practice Implications 
Despite limitations, the framework and typology developed from the study 
contribute to a better understanding of the experiences of OET in women diagnosed with 
ER+BC. Providers can use the framework and typology to guide conversations with 
women who have received a prescription for OET following a diagnosis of ER+BC. Both 
the framework and typology suggest that women might benefit from a clearer 
understanding of the benefits, risks, and side effects of OET early on, and obtaining 
more assistance in managing the side effects, and more decision support in the form of 
intentional discussions about decisions to continue OET or to suspend it.  
Findings from the dissertation are immediately translatable into practice in the 
following ways. First, providers are now aware of the difficult and fundamental choice 
some survivors must make between living longer and the quality of their lives. Therefore, 
they now can routinely engage survivors in meaningful discussions and provide support 
as they make this life-altering decision. Second, providers know now that types, sources, 
and content of OET information can impact the quality of decisions women with ER+ 
breast cancer make about their OET. Therefore, providers should be prepared with 
numerous types, sources, and content of OET information that has been verified and 
that can be trusted in order to ensure that the patient makes a quality decision. Third, 
although several sources of support are able to meet needs identified by this population, 
only the sources of provider and husbands are able to meet all needs identified by study 
participants. Therefore, providers need to be mindful that while information alone may be 
enough for some ER+BCS, most ER+BCS will need more significant interactions with 
providers if they are to continue OET for the recommended duration. 
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5.7 Conclusion 
Adverse side effects from OET are a common experience shared by women with 
ER+BC. The stories provided by the participants reflect the significance of the 
experience of OET side effects in these women and how their experience compromises 
quality health outcomes. The study serves as a call to action for healthcare providers to 
provide side effect management strategies and decisional support to ER+BCS 
throughout their OET experience. 
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DEMOGRAPHIC and TREATMENT FORM 
How old are you today?  ____ 
 
Are you Hispanic or Latina? 
No _____ (1) 
Yes _____ (2) 
 
What is your marital status? 
single _____ (1) 
single, living with partner _____ (2) 
married _____ (3) 
widowed _____ (4) 
other _____ (5) 
 
Do you consider yourself….? 
White/Caucasian ______(1) 
Black/African American  ______(2) 
Asian  ______(3) 
American Indian/Alaskan Native ______(4) 
Native Hawaiian/Pacific Islander ______(5) 
More than one race ______(6) 
 
Which of the following best describes your current work status? 
employed full time _____(1) 
employed part time _____(2) 
homemaker _____(3) 
retired _____(4) 
unemployed _____(5) 
other _____(6) 
 
How much difficulty do you have paying for basics, like housing and 
food? 
No difficulty _____ (1) 
Some difficulty _____ (2) 
A lot of difficulty _____ (3) 
 
Please circle the highest grade of education you completed. 
 1 2 3 4 5 6 7 8 
 9 10 11 12 (high school) 
 13 14 15 16 (college) 
17 18  (master’s degree) 
19 20  (doctorate) 
 
 
Current medications (please list): _________________________ 
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DATE OF DIAGNOSIS:  ____-____-____ 
 
Location:  __ left (1)  __ right (2)  __ bilat (3) 
 
Stage:   
 
 0 _____ (1) 
 I _____ (2) 
 IIA _____ (3) 
 IIB _____ (4) 
 IIIA _____ (5) 
 IIIB _____ (6) 
 
 
Her2 status _______ (+ or -) 
ER    status _______ (+ or -) 
PR    status _______ (+ or -) 
 
 
CHEMOTHERAPY 
 _____ none (0) 
 _____ some (1), # cycles received? _____ 
 
Begin date: ____-____-____ 
End date:  ____-____-____ 
 
 
Complete Treatment Received: 
 _____ surgery alone (1) 
 _____ surgery + XRT (2) 
 _____ surgery + chemo (3) 
 _____ surgery + XRT + chemo (4) 
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DATE OF SURGERY:  ___-___-___ 
 
Type of surgery: 
 _____ lumpectomy (1) 
 _____ MRM (2) 
 _____ RM (3) 
 _____ other (4) 
 
 
RADIATION THERAPY 
 _____ none (0) 
 _____ some (1) 
 
Begin date: ____-____-____ 
End date:  ____-____-____ 
 
 
TAMOXIFEN 
 ___ never used (0) 
 ___ yes, currently using (1) 
 ___ used in past, no current use (2) 
 ___ don’t know (3) 
 
Begin date:  ____-____-____ 
End date:     ____-____-____ 
 
 
AROMATASE INHIBITORS 
 ___ never used (0) 
 ___ yes, currently using (1) 
 ___ used in past, no current use (2) 
 ___ don’t know (3) 
 
Begin date:  ____-____-____ 
End date:     ____-____-____ 
 
 
Date of last treatment 
____-____-____ 
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Interview Guide 
 
I am interested in understanding how women who are prescribed oral endocrine therapy  
(tamoxifen or aromatase inhibitors) make decisions about the therapy – whether to begin 
it, whether to take the medication daily as it is prescribed, and whether to continue it or 
not based on severe side effects. I am particularly interested in how women make these 
decisions when they experience the medication’s side effects. I would like to hear about 
any side effects you have had, and the decisions you have made from the time you first 
started the medication until now. I will ask you several open-ended questions. If you 
don’t want to answer a question, let me know. You can stop the interview at any time. 
 
…………….Think back to when you first became aware that the tamoxifen or aromatase 
inhibitors would be part of your treatment for breast cancer. Tell me as much as you can 
about this time, including where the information came from, what type of information 
(verbal, print, resources) you received, and whether or not you were informed about 
potential side effects  
 
Aim 1 Topic/question guide (responses to side effects) 
 Tell me about any side effects you have had. When did they occur (timing)?  
 Describe to me what happened after you started experiencing each side effect. 
 Were the side effects expected or unexpected?  
 What did you do when you started having side effects? 
 Did you seek or receive any additional information after you started experiencing 
side effects? How did you use this information? 
 Did you receive any help or support in managing the side effects? 
 
Aim 2 Topic/question guide (decisional needs)-no support language 
 Tell me about any decisional needs you may have had regarding your (tamoxifen 
or aromatase inhibitor) (will probe for decisions related to initiation, continuation, 
switching, discontinuation). 
 Tell me how the side effects you were experiencing influenced those needs, if at 
all.  
 What were the things you were unsure about regarding your decision for 
therapy? 
 Did you receive any information that you didn’t understand? 
 Was there anything you were uncertain about regarding your decisions? Did you 
need anything else to make your decision? 
 
Aim 3 Topic/question guide (decisional support) no need language 
 Let’s go back to the major decisions you made regarding your (tamoxifen or 
aromatase inhibitor) and the help or support you had or would have liked to have 
made those decisions.  
o Tell me about the help or support you actually received when you were 
making important decisions about your medication (probe based on 
answers to questions above). 
o Tell me about the help or support you would have liked to have received.  
 Sometimes when we make decisions, things can happen that we do not find 
helpful. We might not get the information we need, we might get inaccurate 
information, we might not have anyone to talk to about our decisions, and things 
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like that…  Tell me about things that might have happened, if any, that got in the 
way of your decision making. 
 
Aim 4 Topic/question guide (process over time) 
 Now, I would like to construct a timeline with you in which we plot the information 
you have given me over the time from when you have been prescribed OET until 
now.   
 Let’s begin with when you were first aware you would be prescribed OET….  
(Construct the timeline for each critical decision.  For each critical decision, 
review the decisional needs and decisional supports that the participant said 
accompanied each decision.  For each decision, ask “Have we forgotten 
anything?” or “Shall we add anything here?”) 
 Eventually, we would like to develop strategies that would help women make 
decisions about their OET. What might these strategies include? What might 
have been (would be) helpful for you? 
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October 13, 2014 
 
 
Jennifer Milata, MSN, RN, ACNS-BC 
Pre-doctoral fellow 
Indiana University School of Nursing 
1111 Middle Drive 
Indianapolis, IN 46220 
 
 
Dear Mrs. Milata: 
 
This letter is to provide my strong support for the submission for your R36 application 
“The oral endocrine therapy decision making process in women with breast cancer”. 
Specifically, I can help you in troubleshooting any difficulties in accessing that patient 
population, including patients seen at Eskenazi Health. Your sponsor, Janet Carpenter, 
PhD, RN, FAAN is a Full Member of the cancer center with access to patients and 
clinician colleagues.    
 
Best wishes,  
 
 
Kathy D. Miller, MD 
Ballve’ Lantero Scholar in Oncology 
Co-Director of the IU Simon Cancer Center Breast Cancer Program 
Associate Professor of Medicine 
Department of Personalized Medicine 
Division of Hematology/Oncology 
IU School of Medicine 
 
cc: Janet S. Carpenter, PhD, RN, FAAN carpentj@iu.edu 
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